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Breakdown of natural mechanisms of immune tolerance towards “self” anti-
gens can result in autoimmune or allergic disease development. There is con-
siderable experimental evidence that the response to antigen which might in-
clude full immunity or immune tolerance induction is dependent on the acti-
vation status of the antigen presenting dendritic cells. Current therapeutic op-
tions deplete immune cell populations, interfere with immune cell trafficking 
to the tissues, or inhibit inflammatory cytokine function and lymphocyte sig-
naling. Although these treatments can be effective for certain diseases, they 
can also cause significant adverse effects and it is unlikely that they could in-
duce stable, long-term immune tolerance. Cellular therapies using either toler-
ogenic dendritic cells or regulatory T cells may be able to achieve it. This the-
sis is focusing on cell-mediated induction of immune tolerance and consists of 
two parts. The studies described in Part I report the development of strate-
gies for possible treatment of Inflammatory Bowel Diseases (IBD).  Induction 
of immune tolerance, in IBD mouse model, with the use of regulatory T 
(Treg) cells generated in vitro by specific activation of naive T cells was 
achieved.  Additionally Treg cells were also shown to be induced in vivo and 
restore intestinal immune tolerance with the use of adeno-associated virus 
(AAV) vector-based gene delivery. In relation to the use of AAV vector, Part 
II of this thesis is addressing the possibilities of tolerance induction to AAV 
capsid or transgene specific immune responses which can develop after   AAV
-based therapy.  
 
Part I   
Development of new treatment strategies for Inflammatory Bowel Diseases, 
which is a group of diseases considered to be autioimmune, is of great interest 
as currently there is no curative treatment. Cell and gene therapy approaches 
have been recently studied in relation to the inhibition of inflammation in the 
gastrointestinal tract. Treg cells have the ability to suppress immune responses 
and to sustain systemic immune balance. Therefore Treg cells have the poten-
tial to prevent inflammatory disorders by induction of immune tolerance. The 
major limitation to the use of natural Treg (nTreg) cells is their low availability 
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and unstable phenotype profile upon ex vivo expansion. Hence, use of in vitro 
generated induced Treg (iTreg) cells represents a good alternative. Currently, 
there are several techniques available to generate induced T regulatory (iTreg) 
cells, nevertheless all of them are to some extend impended with their own 
limitations. Therefore, establishing new, improved methods of iTreg genera-
tion is of great interest. The goal of the experiments presented in Chapter 2 
was to develop a new, straightforward method to generate in vitro functional 
and stable iTreg cells from CD4+CD25- human cells. Generated iTreg cells 
(TregPMA) proved to be functional in vitro in a mixed lymphocyte reactions 
(MLR’s) as they suppressed proliferation of responder cells in a dose depend-
ent manner. The protocol to generate TregPMA in vitro was also applied to 
murine cells. It has been described in Chapter 3. Functionality of the generat-
ed murine iTreg was demonstrated by amelioration of experimental colitis in 
vivo in a mouse model of IBD.  
Also gene and cell therapy approaches have been recently studied in order to 
induce regulatory T (Treg) cells that would be able to inhibit inflammation in 
different tissues. In Chapter 4 a gene delivery approach to promote Treg cells 
in vivo was explored. The delivery of regulatory T-cell epitope 167 (Tregitope 
167) by adeno-associated virus (AAV) vector proved to induce Treg cells in 
vivo and ameliorated the experimental colitis. This study identifies AAV-based 
Tregitope 167 delivery as a new anti-inflammatory approach for induction of 
immune tolerance by Treg cells and in consequence possible treatment of au-
toimmune and inflammatory disorders on an example of IBD model.  
Part II 
The main obstacle in AAV-based gene delivery is the humoral immune re-
sponse against AAV vector capsid that appears after primary AAV delivery. 
The neutralizing antibody (NAB) level that rises against AAV capsid, inhibit 
the AAV vector transduction upon re-administration of the AAV vector of 
the same serotype. In Chapter 6 we demonstrate in a murine model that cross 
administration of AAV serotypes 5 and 1 can be an alternative for re-
administration due to the lack of cross-reactivity of the NAB. Additionally, in 
Chapter 7, we explore different immune suppressive regimens for their ca-
13 
pacity to decrease circulating anti-AAV NAB level that rises after primary 
AAV vector gene delivery. The aim of this study was to define the immune 
suppression strategy and time frame in which the decrease of the anti-AAV 
NAB level would allow the AAV re-administration.  
Another concern in AAV vector-based gene therapy is the potential develop-
ment of immune responses against the transgene product which might lead to 
loss of expression of the therapeutic transgene. Therefore, strategies to induce 
tolerance towards the transgene product are needed. In Chapter 8, we 
demonstrate the feasibility to use mir-142-3p target sequences to prevent im-
mune responses against the transgene product after intramuscular AAV vector 
delivery.  
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Part I 
 
Chapter 1 
 
Introduction Part I 
Gene and cell therapy based treatment strategies for                   
inflammatory bowel diseases  
 
Sander van der Marel, Anna Majowicz,  Sander J. H. van Deventer,   
Daniel W. Hommes and Valerie Ferreira 
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Abstract 
Inflammatory bowel diseases (IBD) are a group of chronic inflammatory dis-
orders most commonly affecting young adults. Currently available therapies 
can result in induction and maintenance of remission, but are not curative and 
have sometimes important side effects. Advances in basic research in IBD 
have provided new therapeutic opportunities to target the inflammatory pro-
cess involved. Gene and cell therapy approaches are suitable to prevent in-
flammation in the GI tract and show therefore potential in the treatment of 
IBD. In this review, we are presenting the current progress in the field of both 
gene and cell therapy and future prospects in the context of IBD. Regarding 
gene therapy, we focus on viral vectors and their applications in preclinical 
models. The focus for cell therapy is on regulatory T lymphocytes and mesen-
chymal stromal cells, their potential for the treatment of IBD and the progress 
made in both preclinical models and clinical trials.     
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Introduction 
Inflammatory bowel diseases (IBD) are chronic inflammatory diseases most 
commonly affecting young adults [1-3]. The exact pathogenesis is unknown, 
but it is widely accepted that IBD result from an inappropriate response of a 
defective mucosal immune system to the intestinal flora and other luminal 
antigens [4-6].  
IBD include two major disorders: ulcerative colitis (UC) and Crohn's disease 
(CD). These disorders have distinct and overlapping pathologic and clinical 
characteristics [7]. UC is a relapsing non-transmural inflammatory condition 
that is limited to the colon [8]. Patients characteristically present with bloody 
diarrhoea, passage of pus, mucus, or both, and abdominal cramping [8]. CD is 
a relapsing, transmural inflammatory disease of the gastrointestinal (GI) 
mucosa that can involve the entire GI tract from the mouth to the anus [8]. 
Patients characteristically present with discontinuous involvement of various 
portions of the GI tract and the development of complications including stric-
tures, abscesses, or fistulas [8]. IBD are associated with a considerable reduc-
tion in quality of life of the patients [9-11] and currently no curative treatment 
options are available. Conventional therapeutics cannot prevent complications 
in IBD and although novel treatment strategies, including TNF-neutralizing 
antibodies, have greatly increased the therapeutic armamentarium, many pa-
tients still have to undergo surgery [12]. For this reason, the development of 
new treatments to prevent initiation of inflammation and more important al-
low for long term remission is required. 
Gene and cell therapy approaches are more and more considered in relation to 
the prevention of inflammation in the GI tract. Gene therapy consists of the 
insertion or alteration of genes within an individual's cells to treat disease. Cell 
therapy describes the process of introducing new cells into a tissue in order to 
treat a disease. Both approaches have been applied successfully in a clinical 
setting for a broad range of diseases either separately or together, including 
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early stage clinical development for IBD [13-23]. Here we discuss current pro-
gress in the field and future treatment prospects in the context of IBD. 
Gene therapy as treatment for IBD 
To facilitate the uptake and the expression of the transgene in the target cell,  
a vector is required. Vectors can be non-viral or viral. The choice of a safe and 
reliable vector that can mediate long term gene transfer to both dividing and 
non-dividing cells is of vital importance for a gene therapy approach. Alt-
hough viral vectors are created from pathogenic viruses, they are modified in 
such a way as to minimize their pathogenicity. This usually involves the dele-
tion of a part of the viral genome critical for viral replication. Such a virus can 
efficiently infect cells and has the potential for long term stable gene expres-
sion. In the gene therapy section of this review we will focus on viral vectors 
that have been used successfully in gene therapy applications in recent years 
[14, 15], are able to target the gut [24-32] and can therefore be considered for 
gene delivery in the GI tract, namely retroviral, lentiviral, adenoviral and 
adeno-associated viral vectors (for an overview see: Table 1 or Figure 1).  
For an overview of non-viral delivery methods to the intestine we recommend 
the review from O’Neill et al [33].  
 
Retro- and lentiviral vectors  
Retroviral vectors were used for the first time in a clinical setting over 20 years 
ago [34-36] and are among the most commonly used vectors in gene therapy. 
Retroviral particles require disruption of the nuclear membrane to gain access 
and therefore need cell division for entering the cell [37]. Retroviruses have 
been demonstrated to be able to transduce intestinal epithelial cells [24-26], 
although at a low efficiency. At the contrary, intestinal epithelial cells can be 
transduced efficiently by lentiviruses [27] which are a sub-class of retroviruses. 
The lentiviruses have an advantage over retroviruses as vectors in gene thera-
py because of their ability to transduce non-dividing cells [38, 39]. Further-
more the lentivirus did not induce mucosal damage or distribute beyond the 
1 
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distal colon [27] and appeared therefore as a potential vector for gene delivery 
in the treatment of IBD.  
However, a safety issue to be considered with both retro- and lentiviral vec-
tors is their potential to integrate at many sites in the human genome [40, 41]. 
Those genomic integrations can result in insertional mutagenesis causing can-
cer development as has been observed in clinical trials [19, 42-44]. Even 
though significant improvements in lentiviral vector safety have been achieved 
in recent years [45], the concern for random integration remains and needs to 
be addressed [46, 47] before these vectors can be considered as safe tools for 
gene therapy applications in IBD. 
 
Adenoviral vectors 
Despite the fact that adenoviruses are pathogenic viruses and can cause mor-
bidity, especially in immune-compromised patients [48], adenoviral vectors 
have been frequently used in gene therapy due to their broad tissue tropism 
and lack of integration into the host genome [49]. Gene therapy using adeno-
viral vectors has shown potential in the treatment of colitis in preclinical mod-
els [28-30]. For example a single systemic injection of an adenoviral vector 
carrying the Interleukin-10 (IL-10) transgene was sufficient not only to pre-
vent the onset of colitis but also to induce clinical and histological remission 
in mice with established disease [29]. Additionally Schmiedlin-Ren and col-
leagues demonstrated that intestinal epithelial cells of IBD patients can be 
efficiently transduced ex vivo by adenoviral vectors [50]. All together, these 
results suggest that targeting of the inflamed intestine through the luminal 
route can be possible using adenoviral vectors [50]. 
However, hematologic and hepatic toxicities were observed in animal studies 
after injection with high vector doses [51-53], which imply that further devel-
opment in generating a new type of adenoviral vector is necessary before con-
sidering clinical applications. Recently a gutted adenovirus, devoid of all viral 
coding sequences, was shown to induce less toxicity [54] after delivery. How-
ever, this finding, if promising for future therapeutic applications, needs fur-
ther exploration.  
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AAV vectors 
The non-pathogenic, replication-deficient adeno-associated virus (AAV) holds 
promise for gene therapy. The AAV vector has a good safety profile as it re-
mains predominantly episomal [55]. In general, 99% of recombinant AAV are 
maintained as episomal copies [56], indicating a very low risk of insertional 
mutagenesis compared with retroviral vectors. Furthermore, AAV vectors are 
able to transduce both dividing and quiescent cells [57, 58] and were demon-
strated to be effective as gene therapy vectors in several promising preclinical 
models for autoimmune and inflammatory disorders [59-66]. The therapeutic 
potential of the AAV as a vector in gene therapy has also been demonstrated 
in a clinical setting in recent studies [67-77]. 
AAV vectors were shown to be able to target the GI tract [31, 32] and long 
term transgene expression post AAV treatment was reported which in relation 
with the high turn-over of intestinal cells, suggests that transduction of the 
slow-dividing intestinal stem cells was achieved [31, 32].  However, no data 
are presently available about the treatment of experimental colitis with AAV 
vectors. 
 
Cell therapy as treatment for IBD 
Cell-based therapies aim to introduce new cells into a tissue in order to treat a 
disease and can permit the replacement of function [78], or restore the home-
ostasis of the immune system [79]. In the last 50 years hematopoietic stem cell 
transplantation has been developed as a curative option for inherited disorders 
and hematologic or lymphoid cancers [13, 80], leading the way toward innova-
tive therapies for other illnesses. Recent results obtained from animal models 
and early human clinical trials in graft versus host disease but also CD showed 
that either regulatory T lymphocytes or mesenchymal stromal cells may be of 
clinical relevance for the treatment of IBD (for an overview see: Table 2 or 
Figure 1). 
1 
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Regulatory T lymphocytes  
The immune system contains a population of T cells, called regulatory T lym-
phocytes that are specialized in immune suppression [81, 82]. Low level auto-
immunity may occur in the intestine as a result of the presence of the microbi-
al flora or auto-reactive T cells. Regulatory T lymphocytes are generated in the 
mesenteric lymph nodes and subsequently migrate and expand in the gut [83], 
thereby preventing progress to chronic autoimmune disease [84, 85]. These 
cells are able to suppress an immune response both by cell contact (e.g. killing 
or functional modulation of antigen presenting cells or effector T cells) and 
soluble factor dependent mechanisms (e.g. secretion of immunosuppressive 
cytokines or deprivation of cytokines necessary for the expansion/survival of 
responder T cells) [86, 87]. Antigen specific regulatory T lymphocytes have 
been described as having more therapeutic efficacy than polyclonal regulatory 
T cells [88-90]. In IBD the antigenic targets are not totally defined [6] and cell 
therapy would have to be restricted to polyclonal cells. However, regulatory T 
lymphocytes do not need to be antigen specific in order to suppress immune 
responses as a result of bystander suppression and infectious tolerance [91, 92]. These 
are general mechanism through which regulatory T lymphocytes are able to 
create a regulatory milieu in vivo [91, 92] and could introduce tolerance in IBD. 
Regulatory T lymphocytes were shown to be effective in both the cure and the 
prevention of experimental colitis in multiple animal models [93-96]. It was 
shown for example that transfer of regulatory T lymphocytes into mice with 
colitis led to resolution of the lamina propria infiltrate in the intestine and re-
appearance of normal intestinal architecture [96]. Therefore regulatory T lym-
phocytes could be used as a therapeutic tool in IBD where their homeostasis 
is disturbed [97, 98]. 
Among the different T cells with suppressive activity the 
CD4+CD25highFOXP3+ regulatory T cell (Treg) [82] and the type 1 regulatory 
T cell (Tr1) [81] subsets are the most well-defined so far. The Tr1 is typically 
characterized based on the cytokine production profile (IL-10high) [81] and 
Treg by the expression of the transcription factor Forkhead box p3 (FOXP3 
1 
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in humans/Foxp3 in mice), which appears to function as the master regulator 
in their development and function [99, 100].  
Treg and Tr1 have the potential to prevent or cure colitis [93-96] and a fa-
vourable safety profile in phase I clinical trials was demonstrated [21, 101]. 
Tr1 were shown to have a preliminary efficacy signal in patients in a phase I 
clinical trial for refractory CD (unpublished data, UEGW 2010-ABS-577). Cur-
rently the efficacy of Treg and Tr1 based cell therapy awaits further confirma-
tion from phase II/III clinical trials but overall these results emphasize that 
both Treg and Tr1 are promising tools for therapeutic applications in IBD. 
 
Mesenchymal stromal cells  
Mesenchymal stromal cells (MSCs) are non-haematopoietic stromal cells ex-
hibiting multi-lineage differentiation capacity and the ability to mediate immu-
nosuppressive and anti-inflammatory effects [102-105]. The exact mechanism 
by which MSCs suppress the immune system is not fully understood. It is 
known however that MSCs have immunosuppressive features in common 
with regulatory T lymphocytes, as for example preventing the maturation of 
antigen presenting cells (APCs) [102] or physically hinder T cells from con-
tacting APCs [103]. Additionally it was shown that FOXP3 expression confers 
a greater immunosuppressive potential to MSCs [106].  
MSCs can be isolated from various tissues [107-109] and were shown to ame-
liorate experimental colitis [110, 111]. In humans, MSCs obtained from adi-
pose tissue induced healing in perianal fistulas in patients with CD [17]. Fur-
thermore, in a phase I clinical trial, administration of autologous bone marrow
-derived MSCs was shown to be safe and feasible in the treatment of refracto-
ry CD [22]. Additionally it was demonstrated that ex vivo expanded autologous 
bone marrow-derived MSCs are a safe and feasible approach for intrafistular 
injections in patients with CD [23]. These results [17, 22, 23] show potential 
and await further verification in phase II/III clinical trials which are currently 
being conducted. 
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Can gene and cell therapy overlap in the treatment of  
IBD? 
The phenotype and function of lymphocytes can be modified using viral vec-
tors, to create tools for a cell therapy approach in the treatment of autoim-
mune, and inflammatory disorders [112] and by consequent IBD [113-116]. It 
was shown that the ex vivo targeting of spleen derived CD4+ T cells by a retro-
viral vector expressing IL-10 was able to generate Tr1 that prevented colitis in 
an experimental model of IBD [113].  
Using the same approach, fully functional Treg were generated by transduc-
tion of T cells with a Foxp3 transgene. These cells were able to suppress auto-
immunity and graft rejection in vivo [89, 115, 117, 118]. Furthermore, Hori and 
colleagues showed that the in vitro generated Treg prevented colitis in a mice 
model of IBD [115]. 
Additionally it was demonstrated that Treg can be efficiently transduced to 
express functional antigen-specific receptors [116]. Adoptive transfer of small 
numbers of these transduced Treg was associated with antigen-specific, dose-
dependent amelioration of experimental colitis in mice (Table 3). 
 
General considerations relevant for IBD 
The route of therapeutic delivery is important when considering gene or cell 
therapy in relation with IBD. The mucus lining in the intestine is a barrier for 
gene transfer via the luminal route [119] and the clearance of viral particles by 
the liver represents a problem for the  systemic delivery [120]. Nonetheless, as 
described above it has been shown that transduction via these routes is possi-
ble and that long term transgene expression can be achieved. Possible viral 
vectors, as for example the AAV based viral vectors seem to have the poten-
tial to transduce the GI tract, but the optimization of gene targeting to the gut 
needs to be further explored. This could be achieved by testing different AAV 
serotypes [121] or modifying the AAV capsid [122]. A promising method is 
the so called DNA shuffling method. DNA shuffling is a method whereby 
genes are rearranged to form hybrid genes with new properties [123]. This can 
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be done using polymerase chain reactions, as described by J. Cohen [123]. If 
this approach is used for genes encoding AAV capsid proteins it can allow for 
the development of cell type specific vectors [124] and thereby shows promise 
for creating a gut targeting AAV. Furthermore chemical redirection of the 
AAV capsid shows potential in engineering vectors with novel tissue tropisms 
[125]. Chemical engineering refers to a process whereby the amino acids on 
the surface of the AAV capsid are changed [125]. This method has proven to 
be successful in redirecting the AAV from liver to skeletal and cardiac muscle 
following systemic administration in mice [125] and could therefore have po-
tential in directing the AAV to the GI tract.  
Due to the presence of stem cells in the intestinal crypts [126] the gut is sug-
gested to be an interesting target for therapeutic gene transfer. Every crypt in 
the intestine contains four to six independent stem cells [126]. Stem cells are 
believed to divide very rarely [126]. Therefore, these cells could have the po-
tential to permit long term, stable transgene expression after transduction. It 
has been shown that intestinal stem cells can be transduced in vitro using a ret-
roviral vector [127]. Long term transgene expression observed in the gut after 
AAV vector delivery in mice suggests that transduction of intestinal stem cells 
is possible in vivo [31, 32].  
 
Future prospects 
The knowledge about the pathophysiology of IBD is growing and it has be-
come clear that significant genetic as well as phenotypic heterogenecity exists 
within both CD and UC [128]. These findings offer opportunities for more 
specifically targeted interventions. Gene or cell therapy based treatment strate-
gies can be adapted and exclusively targeted at certain subgroups within the 
IBD patient population with characterized genetic defects linked to the im-
pairment of their gut physiology. 
Strategies to optimize gene therapy approaches include the use of a tissue spe-
cific promoter enabling site specific expression of a transgene. Recently, gut 
specific promoters have been described [129-131]. The A33-antigen promoter 
1 
27 
for example strictly depends on the presence of the intestine-specific tran-
scription factor Cdx1 which is essential for the unique intestinal expression 
pattern of the A33-antigen gene [129, 131]. Therefore this promoter is a 
promising candidate to induce intestine specific expression of a transgene 
[131].   
 
Concluding remarks 
IBD are a group of chronic inflammatory disorders most commonly affecting 
young adults and currently there is no curative treatment available. A gene 
therapy approach for the local expression of therapeutic agents in the gut or a 
cell therapy approach using regulatory T cells or mesenchymal stromal cells 
may offer an alternative treatment for gastrointestinal inflammation. Both 
gene and cell therapy approaches have shown promising results in preclinical 
models of IBD. Cell therapy approaches have been translated to a clinic set-
ting and currently phase II/III clinical trials for the treatment of refractory 
CD are in progress. Concerning gene therapy, further development of viral 
vectors delivery to the gut as well as long term efficacy are still needed, but pre
-clinical data are promising. 
Overall, both gene and cell therapy have the potential to become important 
players in the next generation of therapeutic agents that will be aimed at un-
met medical needs as those that exist in IBD.  
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in vitro within 4 days by a two step activation protocol  
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Abstract 
The significance of regulatory T cells in the control of tolerance shows prom-
ise for new therapeutic applications. Cell therapy with regulatory T cells has 
the potential to become a new patient tailored approach in the treatment of 
allergic, autoimmune or inflammatory disorders. Our objective was to define a 
new, straightforward protocol to generate sufficient numbers of inducible reg-
ulatory T cells in vitro applicable for future clinical trials.  
With the use of a novel, two-step T cell activation protocol we generate in 
vitro, within 4 days regulatory T cells. The phenotype and functionality of 
those cells assessed by flow cytometry and MLR’s were sustainable over a pe-
riod of at least 30 days in culture. These cells could be applied either alone or 
together with naturally occurring regulatory T cells in the treatment of allergic, 
autoimmune or inflammatory disorders. 
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Introduction 
Regulatory T cells (Treg) are key players in maintaining peripheral tolerance, 
preventing autoimmune diseases and limiting chronic inflammation [1]. There-
fore, strategies that aim for therapeutic tolerance induction may take ad-
vantage of the functions of Treg [2]. 
The transcription factor FOXP3 is generally considered as the master regula-
tor in the development and function of Treg [3-5]. However FOXP3 expres-
sion can also be induced in human T effector cells which do not have sup-
pressive activity [6]. Thus, FOXP3 expression is necessary, but not sufficient 
to identify functional Treg and other markers have to be taken in considera-
tion as well [6].  
Treg are able to suppress an immune response both by cell contact (e.g. killing 
or functional modulation of antigen presenting cells or effector T cells) and 
soluble factor dependent mechanisms (e.g. secretion of immunosuppressive 
cytokines or deprivation of cytokines necessary for the expansion/survival of 
responder T cells) [7]. They are considered to be an attractive tool for the 
treatment of a broad range of diseases [8-12]. Recently, different groups have 
been able to expand functional, naturally occurring regulatory T cells (nTreg) 
ex vivo [13-15]. In Phase I clinical trials a favorable safety profile was shown 
for nTreg in the treatment of acute graft versus host disease [16, 17]. However 
it was reported by the same group [18] that cellular therapy using Treg in-
duced in vitro has several potential advantages over nTreg, including ease of 
isolation, increased number of the starting population, greater proliferation 
potential and reduced production costs [14]. Additionally multiple defects in 
nTreg in patients with autoimmune diseases have been described [19] which 
could prevent the use of these cells for the treatment of autoimmunity. This 
problem could be overcome by using Treg induced in vitro. These induced 
Treg (iTreg) like nTreg, have been shown to suppress auto-, and alloreactivity 
in vivo [18, 20]. Furthermore, it has been demonstrated that the physiologic 
generation of iTreg from naive T cells in vivo, is essential for establishing oral 
tolerance [21] and that iTreg generated in vitro can act in synergy with nTreg 
from the same donor to restore and maintain tolerance in vivo [22]. It is there-
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fore postulated that iTreg could have an important, non-redundant role in 
establishing tolerance [21-23]. Consequently iTreg generated from CD4+CD25
- T cells in vitro have potential, either alone or together with nTreg, for the 
treatment of allergy, autoimmune or inflammatory disorders. This approach 
has been explored before, whereby stimulation with anti-CD3 was an im-
portant element [24, 25], as anti-CD3 up-regulates FOXP3 expression in vitro 
[26]. However, in contrast to nTreg FOXP3 expression seems to decline over 
time in iTreg [26] resulting in a loss of regulatory function. Apart from activa-
tion with anti-CD3 [24, 25], several other groups have used different strategies 
to generate iTreg in vitro, including use of TGFβ, all-trans-retinoic acid and the 
recently discovered regulatory cytokine IL-35 [27, 28]. All these technologies 
require more or less extensive cell handling and processing and it remains un-
certain whether these methods will enable generation of sufficient iTreg under 
Good Manufacturing Practices (GMP). 
We have established a new, simple and robust method to generate stable and 
functional iTreg from human CD4+CD25- T cells in vitro. This method is com-
posed of two steps of activation with an initial PMA/ionomycin activation 
step followed by anti-CD3 stimulation in presence of a low dose of Interleu-
kin-2 (IL-2). This approach has the advantage of promoting the conversion of 
CD4+CD25- T cells to a high number of functional iTreg and could be suita-
ble for application under GMP. Furthermore, by making use of substances 
that are well known, simple to obtain and relatively low priced this protocol 
could be easy to employ in a routine laboratory setting. 
Material and methods  
Samples 
Buffy Coats from healthy adults were obtained from the blood bank (Sanquin, 
the Netherlands). The study was reviewed and approved by the ethical board 
of Sanquin Blood Supply Foundation. Peripheral Blood Mononuclear Cells 
(PBMC’s) were extracted using cell preparation tubes with sodium citrate (BD 
Vacutainer® CPT™, BD Biosciences). 
Isolation and stimulation of CD4+CD25- T cells  
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CD4+CD25- T cells were obtained from PBMC’s by means of negative selec-
tion using the naive CD4+ T cells isolation kit (Miltenyi Biotec®) and CD25 
microbeads (Miltenyi Biotec®) for additional CD25 depletion to ensure that 
no CD4+CD25+ cells remained, as described before [29]. Both isolation steps 
were performed according to the instructions of the manufacturer with the 
use of LD columns (Miltenyi Biotec®). Routine evaluation of the obtained 
CD4+ CD25- population analyzed by flow cytometry showed a purity of 
>95%.  
CD4+CD25- T cells were re-suspended in X-vivo15 human medium (Lonza) 
containing 5% human serum (Lonza) at 2.5 x 105 cells/ml and subsequently 
activated with PMA (10 ng/ml, obtained from Sigma-Aldrich) and ionomycin 
(250 ng/ml, obtained from Sigma-Aldrich). After 48 h cells were washed twice 
with PBS, re-suspended in medium and activated with 10 μg/ml anti-human 
CD3 (Clone OKT3, eBioscience) in the presence or absence of IL-2 (50 U/
ml, obtained from eBioscience). Cells were cultured in 96-well, flat bottom 
plates. IL-2 (50 U/ml) was added every 72 h.  
Phenotypical characterization  
Cells were analyzed using flow cytometry (FACSCalibur, BD Biosciences) and 
CellQuest Pro software (BD Biosciences). For Treg staining the human regu-
latory T cell staining kit was used (PE-conjugated FOXP3, clone PCH101, 
FITC-conjugated CD4, clone RPA-T4 and APC-conjugated CD25, clone 
BC96) obtained from eBioscience. To assess the specificity of the PCH101 
clone we performed FOXP3 staining with clone PCH101 (eBioscience), 
259D/C7 (BD biosciences) and 3G3 (Miltenyi Biotec®) in parallel, according 
to the instructions of the manufacturer (experiments in triplicate, n=2, data not 
shown). Overall little (<5%), non significant differences were observed in our 
experimental setup and therefore we continued with PCH101 as this clone has 
been validated for FOXP3 detection [30]. 
Additional monoclonal anti-human antibodies used in this study were as fol-
lows: anti-CD127 (PerCP Cy5.5-conjugated, clone eBioRDR5), anti-CD4 (PE-
conjugated, clone RPA-T4), anti-CD152 (CTLA-4, PE-conjugated, clone 
14D3), anti-AITR/GITR (PE-conjugated, clone eBioAITR), anti-OX40 
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(CD134, FITC-conjugated, clone ACT35), anti-ICOS (APC-conjugated, clone 
ISA-3) and anti-IL-10 (APC-conjugated, clone JES3-9D7) obtained from   
eBioscience. The viability dye 7-AAD (BD Biosciences) and the scatter dot 
plot were used to exclude dead cells from analysis. For intracellular staining 
(FOXP3, CTLA-4 and IL-10), cells were fixed and permeabilized using the 
FOXP3 staining buffer set from eBioscience. The IL-10 staining was per-
formed intracellularly, as it has been described before [29]. High expression of 
a marker is defined as fluorescence intensity greater than 100, as it has been 
described before [31]. Regulatory markers were followed over time up until 30 
days in culture, with or without supplementation of a low dose of IL-2 (50 U/
ml, every 72 h). As control, CD4+CD25- T cells activated with PMA (10 ng/
ml)/ionomycin (250 ng/ml) followed by IL-2 (50 U/ml) or anti-CD3 (10 μg/
ml) followed by IL-2 (50 U/ml) were analyzed by flow cytometry after 9 days 
or after 30 days in culture.  
Viability and proliferation 
Viability of the cells was determined by staining with 7-AAD (BD Bioscienc-
es) followed by flow cytometry analysis. Cell number was determined by use 
of the NucleoCounter to assess proliferation rate in culture (NucleoCounter, 
Chemometec). 
Functional characterization 
Regulatory function was analyzed using Mixed Leukocyte Reactions (MLR’s) 
with CFSE stained responder cells [32], described previously as a valuable tool 
to study suppressor T cells [33]. Shortly CFSE labelling: The CellTrace CFSE 
cell proliferation Kit (Molecular Probes, Invitrogen) was used to stain PBMC’s 
from the same donor as the experimental cells according to the manufactur-
er’s instructions. These cells are referred to as responder cells. A final working 
concentration of 5 μM CFSE was used per 5 x 106 PBMC’s, to obtain a 
CFSEhigh stained responder population, as determined by flow cytometry us-
ing different titrations of CFSE. CFSE expression was routinely evaluated 
after staining by flow cytometry.  
MLR 
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CFSE labelled PBMC’s (responder cells) were cultured in 96-well round bot-
tom plates at 2.5 × 104 cells/well with 5 × 104 cells/well irradiated allogenic 
PBMC’s (as feeder cells) in the presence of varying amounts of experimental 
T cells. Autologous PBMC’s as feeder cells for the autologous control, 
CD4+CD25- T cells as negative control and rapamycin (100 ng/ml) as positive 
control were plated out to assess their effect on proliferation. Cell cultures 
were stimulated with 2 μg/ml anti-human CD3. All culture settings were per-
formed in triplicate.  
Experimental T cells, generated with the two-step activation protocol, were 
analyzed for their suppressive function in the described MLR’s after 9 days in 
culture or after 30 days in culture. The MLR was set, after 5 days cells were 
harvested, washed with PBS and the CFSE signal was analyzed by flow cy-
tometry. Routine evaluation during titration experiments showed that prolifer-
ating cells loose their CFSEhigh staining and become CFSElow. Therefore sup-
pression of CFSElow represents the suppression of proliferating responder 
cells compared to control (see: Figure 4.B), as described before  [33]. Cell 
cultures were set with or without a 0.4 μm transwell permeable support sys-
tem (Corning), in order to determine cell contact or cytokine dependence in 
the Treg functionality assay. 
Results  
Induction of a regulatory phenotype in CD4+CD25- T cells     
CD4+CD25- T cells were activated with PMA/ionomycin and subsequently 
with anti-CD3, in the presence of IL-2 (50 U/ml). After 9 days in culture, the 
T cells from four different donors were analyzed by flow cytometry and 55% 
to 83% of the cells were shown to express the classical regulatory phenotype 
(CD4+CD25highFOXP3+, Figure 1.A). Inter-donor variation was observed, 
but for every analyzed donor more than 50% of the CD4+CD25- T cells dif-
ferentiated into (CD4+CD25highFOXP3+) Treg. We will refer to this inducible 
regulatory T cell population as ‘TregPMA’ cells. 
In order to demonstrate the specificity and effectiveness of our two-step acti-
vation procedure, CD4+CD25- T cells from three of the four donors were 
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activated with PMA/ionomycin followed by IL-2 or activated with anti-CD3 
followed by IL-2, as control groups. The cells were analyzed by flow cytome-
try after 9 days in culture. Between 0.1% and 2% of the cells in the anti-CD3/
IL-2 group and between 13% and 31% in the PMA/ionomycin/IL-2 group 
were shown to express the classical regulatory phenotype 
(CD4+CD25highFOXP3+) after 9 days in culture (Figure 1.B).  
Expression of regulatory markers by the TregPMA  
High CD25 expression [34] and down-regulation of CD127 [35, 36] are estab-
lished characteristics of the Treg phenotype in humans. Therefore expression 
of those markers on the surface of the TregPMA was monitored by flow cy-
tometry. Furthermore, we analyzed the expression of CTLA-4, which is linked 
to Treg function [37, 38], glucocorticoid-induced TNF receptor (GITR), 
linked to Treg survival  [1], ICOS, linked to Treg function [39, 40] and OX40, 
also known as CD134, which is linked to Treg homing and survival [41, 1]. 
Additionally, we analyzed the expression of IL-10, a regulatory cytokine that 
down-regulates the expression of T helper cell cytokines, MHC class II anti-
gens, co-stimulatory molecules on macrophages and has been associated with 
Treg function [42].  
The TregPMA demonstrate down-regulation of CD127 and up-regulation of 
CD25, FOXP3, IL-10, CTLA-4, GITR, ICOS and OX40 when compared to 
the PMA/ionomycin/IL-2 control group and to non-activated T cells (Figure 
2).  
To monitor the acquisition of the regulatory phenotype over time by the 
TregPMA in culture, the profile of expression of the established regulatory 
markers CD25, CD127, FOXP3 and IL-10 was analyzed by flow cytometry at 
different time points (Figure 3). A clear up-regulation of the Treg lineage 
transcription factor FOXP3 was observed over time, as well as of the markers 
CD25 and IL-10. CD127 was down-regulated, further confirming the regula-
tory phenotype [35, 36]. For these markers the PMA/ionomycin and anti-
CD3 steps seemed to act synergistically to achieve the expression of a regula-
tory profile. 
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It has to be noted that the expression of CD4 at the cell surface was down-
regulated after the PMA/ionomycin activation step, but was gradually restored 
after anti-CD3 activation, as it was described before [43, 44, 45].  
The expression profiles, determined by flow cytometry of CD4+, CD25high, 
CD127-/low and FOXP3+ demonstrate that within 4 days in culture the   
TregPMA obtain their regulatory phenotype (Figure 3).  
Using the described TregPMA protocol we are able to generate a mean of 2.2 
x 106 TregPMA cells/ml (SD 1.0 x 106; N=3) after 9 days in culture starting 
from 2.5 x 105 CD4+CD25- T cells/ml. The mean cell viability was >95% as 
confirmed by both NucleoCounter and 7-AAD staining (data not shown). 
TregPMA suppress the proliferation of responder cells in vitro  
Since the main functional characteristic of Treg is the capacity to suppress the 
proliferation of responder cells in vitro, the capacity of the TregPMA to sup-
press the proliferation of responder cells was analyzed by MLR’s, after 9 days 
in culture. A fixed number of CFSE labelled responder cells was co-cultured 
with a varying amount of TregPMA (responder cells to TregPMA ratio 1:0, 
1:0.33, 1:0.67 and 1:1.67). The cells of three different donors were analyzed. 
Inter-donor variations were observed, but TregPMA always suppressed the 
proliferation of responder cells in co-culture with an efficacy between 25% 
and 43% (Figure 4.A). The observed effect was proportional to the number 
of TregPMA added in the assay, demonstrating a dose dependent inhibition. 
The separation of TregPMA from the responder cells, in a transwell assay, 
abrogates their suppressive function demonstrating contact-dependent sup-
pression of the proliferation of responder cells (data not shown).   
It has to be noted that the inhibition of proliferation was not due to depletion 
of nutrients or accumulation of waste products as in the negative control the 
addition of an equal amount of CD4+CD25- T cells, instead of the TregPMA 
caused no inhibition of the CFSE division (Figure 4.A and B).  
All together the obtained data show that the TregPMA suppress the prolifera-
tion of responder cells in vitro in a dose and contact dependent manner. 
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Phenotype and function of TregPMA are stable in long term culture 
Since the sustainability of TregPMA phenotype and functionality over time is 
important for possible clinical applications [46], the TregPMA were kept in 
culture for 30 days and analyzed by flow cytometry and MLR’s.  
Expression of regulatory markers after long term culture 
To monitor the sustainability of the regulatory phenotype over time of the 
TregPMA, the profile of expression of the regulatory markers, CD127, CD25, 
FOXP3, IL-10, CTLA-4, GITR, ICOS and OX40 was analyzed by flow cy-
tometry after 30 days in culture. After following our two-step protocol, the 
TregPMA of two different donors demonstrated a sustainable down-
regulation of CD127 as well as up-regulation of CD25, FOXP3, IL-10, CTLA
-4, GITR, ICOS and OX40 when compared to the PMA/ionomycin/IL-2 
control group and to non-activated T cells (data not shown).  
Stable regulatory function of the TregPMA after 30 days in culture 
The capacity of the TregPMA, after 30 days in culture, to suppress the prolif-
eration of responder cells was analyzed by MLR’s. The TregPMA from two 
different donors cultured for 30 days were shown to inhibit the proliferation 
of responder cells (mean inhibition up to 40%). Therefore it can be concluded 
that the regulatory function of the TregPMA is maintained over time in cul-
ture.  
IL-2 contributes to FOXP3 transcription through activation of Stat5 and is 
thereby of importance both for Treg homeostasis and for maintaining their 
suppressive program [47]. Therefore we cultured the generated TregPMA in 
the presence or absence of IL-2 and examined their regulatory properties. 
Cells of two different donors were analyzed by flow cytometry and it was de-
termined that 65% and 70% of the TregPMA express FOXP3 when cultured 
in the presence of a low dose of IL-2, while less than 5% of cells express 
FOXP3 without IL-2 supplementation. Furthermore, the TregPMA, cultured 
in the absence of exogenous IL-2, were not able to suppress the proliferation 
of responder cells in MLR’s (data not shown).  
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Discussion  
This paper describes a new and simple method to generate in vitro, within 4 
days, stable and functional CD4+CD25highFOXP3+CD127-/low iTreg. This  
approach could be easily adapted to clinical application under Good Manufactur-
ing Practices (GMP) and thereby allow the preparation of a sufficient quantity of 
cells to enable use of iTreg for both prevention and subsequent therapy [48]. 
Other techniques to generate iTreg have been reported and are available [27, 
28]. However, the protocol described in this paper presents a straightforward 
and robust alternative, by making use of substances which are well known, 
easy to obtain and relatively low priced.  
Our protocol consists of two steps. The first step is the activation of 
CD4+CD25- T cells with PMA/ionomycin. This combination provides a po-
tent stimulation allowing us to bypass the T cell receptor activation essential 
for Treg development and prevent the emergence of CD4-CD8+ cells in the 
culture [49]. PMA activates protein kinase C [50] while ionomycin is a Ca2+ 
mobilizing agent [51]. This combination has shown to up-regulate CD25 on T 
lymphocytes [49] and a high CD25 expression is a marker of the Treg pheno-
type [34]. Additionally, it was demonstrated that Ca2+ signaling is required for 
the development and function of Treg [52, 53]. Therefore we expected that 
raising the intracellular levels of Ca2+ in CD4+CD25- T cells using ionomycin 
would have a synergistic effect with PMA in starting a regulatory developmen-
tal program in CD4+CD25- T cells. The expression profiles, analyzed by flow 
cytometry, after activation with PMA/ionomycin, show a clear up-regulation 
of the Treg lineage transcription factor FOXP3, as well as of the markers 
CD25 and IL-10. Conform to the regulatory phenotype [35, 36], CD127 was 
down-regulated. 
The second step in our protocol is a step of activation with anti-CD3 in the 
presence of a low dose of IL-2. This second stimulation is needed to maintain 
the regulatory developmental program, since the initial up-regulation of 
FOXP3 expression, as well as the expression of CD4 on the cell surface de-
clines in time after only PMA/ionomycin stimulation. Anti-CD3 was used for 
this purpose since it has been shown to maintain and expand Treg [54, 55] 
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and restore CD4 expression [45]. We show here that, for the established regu-
latory markers, CD25high, CD127-/low, and FOXP3+ [34-36] the PMA/
ionomycin and anti-CD3 steps seem to act synergistically to achieve the ex-
pression of a regulatory profile within 4 days in culture. Furthermore, the anti-
CD3 activation step in our protocol restores the CD4 expression, which is 
down-regulated after the PMA/ionomycin activation step. 
IL-2 contributes to FOXP3 transcription through activation of Stat5 and is 
thereby of importance both for Treg homeostasis and for maintaining their 
suppressive program [47]. Therefore we cultured the generated TregPMA in 
the presence or absence of IL-2 and examined their regulatory phenotype and 
function. We demonstrate that the expression of regulatory markers and capa-
bility of suppressing proliferation of responder cells in vitro are dependent on 
exogenous IL-2. Furthermore we show that in the presence of IL-2 the phe-
notype and function are stable over a long period of time.  
 
Conclusions  
Generating sufficient numbers of iTreg from human PBMC’s and preserving 
their regulatory function for clinical application still proves to be difficult. In 
this paper we describe a protocol which permits to induce a stable regulatory 
phenotype and function in CD4+CD25- T cells in vitro, within 4 days. We pre-
sent a good alternative to previously established methods [27, 28] by making 
use of substances which are well known, simple to obtain and relatively low 
priced. Therefore, our two-step activation protocol could be easily adapted to 
routine laboratory settings, for future clinical applications, using iTreg either 
alone or together with nTreg in the treatment of allergic, autoimmune or in-
flammatory disorders. 
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Abstract 
Background 
Induced regulatory T (iTreg) lymphocytes show promise for application in the 
treatment of allergic, autoimmune and inflammatory disorders. iTreg cells 
demonstrate advantages over natural Treg (nTreg) cells in terms of increased 
number of starting population and greater potential to proliferate. Different 
activation methods to generate iTreg cells result in iTreg cells that are hetero-
geneous in phenotype and mechanisms of suppression. Therefore it is of in-
terest to explore new techniques to generate iTreg cells and to determine their 
physiological relevance.   
Methods 
Using phorbol myristate acetate (PMA)/ionomycin and anti-CD3 activation 
of CD4+CD25- cells we generated in vitro functional CD4+CD25+ iTreg 
(TregPMA) cells. Functionality of the generated TregPMA cells was tested in 
vivo in a mouse model of inflammatory bowel disease (IBD) - CD45RB trans-
fer colitis model.  
Results 
TregPMA cells expressed regulatory markers and proved to ameliorate the 
disease phenotype in murine CD45RB transfer colitis model. The body weight 
loss and disease activity scores for TregPMA treated mice were reduced when 
compared to diseased control group. Histological assessment of colon sec-
tions confirmed amelioration of the disease phenotype. Additionally, cytokine 
analysis showed decreased levels of proinflammatory colonic and plasma IL-6, 
colonic IL-1 β and higher levels of colonic IL-17 when compared to diseased 
control group. 
Conclusions 
This study identifies a new method to generate in vitro iTreg cells (TregPMA 
cells) which physiological efficacy has been demonstrated in vivo. 
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Introduction 
T regulatory (Treg) lymphocytes are a cellular component of the immune sys-
tem that suppresses immune responses of effector cells. As a result of their 
ability to control immune responses and to sustain systemic immune balance, 
they have the potential to prevent allergic, autoimmune and inflammatory dis-
orders [1-10] as well as to be an adjuvant therapy for chronic and acute graft 
versus host disease [11].  
The safety profile of Treg cells has been established in phase I clinical trials  
[11, 12] demonstrating that Treg cells are a suitable candidate for therapeutic 
purposes. However a major limitation to the clinical use of natural Treg 
(nTreg) cells is their low availability as they represent only a small percentage 
of the peripheral circulating CD4+ T cell population. In order to overcome 
this issue, several groups have developed different methods to expand nTreg 
cells in vitro when keeping their functionality. Generally the technologies are 
complex, time-consuming and the plasticity of nTreg cell lineage in artificial 
environment during ex vivo expansion can lead to loss of their suppressive ac-
tivity [13]. Furthermore their stage of differentiation makes their expansion in 
vitro a difficult process [14]. 
In vitro induced T regulatory (iTreg) cells represent a good alternative to nTreg 
cells since they have been reported to have similar functionality in in vivo set-
up. Additionally iTreg cells show advantages over nTreg cells in terms of in-
creased number of starting population and greater potential to proliferate  
[15]. Therefore it is of importance to investigate and explore new approaches 
to generate iTreg cells.    
Based on the activating and stimulating properties of phorbol myristate ace-
tate (PMA)/ionomycin and anti-CD3 on T cells [16, 17] we developed a new 
method to generate iTreg cells in vitro, which we refer to as ‘TregPMA’ cells. 
The functionality of the TregPMA cells was assessed in vivo in a mouse model 
of experimental colitis. 
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Methods 
Mice 
BALB/C and C.B.-17 SCID mice (8-10 weeks) were obtained from Harlan 
and maintained in specific pathogen-free conditions. Mouse experiments were 
approved by the local animal welfare committee (University of Amsterdam). 
Generation of regulatory T lymphocytes (TregPMA cells) 
Splenocytes were isolated from BALB/C mice. CD4+ CD25-  T cells were iso-
lated from splenocytes by means of negative selection using the mouse “CD4+ 
T Cell Isolation Kit” followed by “CD25 MicroBead Kit” (Miltenyi Biotec). 
Cells were seeded at day 0 at 1 x 105/well into anti-CD3e (0.5 µg/well, clone 
145-2C11, eBioscience) coated 96-well flat bottom plates (Costar) and cul-
tured in X-VIVO 15 medium (Lonza) at 37°C in a 5% CO2 incubator. On day 
1, cells were activated with PMA (10 ng/ml) and ionomycin (250 ng/ml) and 
at day 2, 3 and 4 supplemented with 20 U/well of IL-2 (eBioscience). On day 
5, prior to use, cells were harvested and treated with “Dead Cell Removal 
Kit” (Miltenyi Biotec).  
Flow Cytometry Analysis 
Cells were analyzed using flow cytometry (FACSCalibur, BD Biosciences). For 
Treg cell staining the mouse “Regulatory T cell Staining Kit” was used which 
consisted of anti-mouse CD4 FITC (clone RM4-5), anti-mouse CD25 APC 
(clone PC61.5) and anti-mouse/rat Foxp3 PE (clone FJK16). Additional mon-
oclonal anti-mouse flow cytometry antibodies used in this study were as fol-
lows: anti-mouse CD152 (CTLA-4) APC (clone UC10-4B9), anti-mouse 
GARP PE (clone YGIC86), anti-mouse/rat CD278 (ICOS) FITC (clone 
C398.4A) and anti-mouse CD134 (OX-40) APC (clone OX86). All antibodies 
were obtained from eBioscience. 
Induction of CD45RB Transfer Colitis Model and treatment with 
TregPMA cells 
Chronic colitis was induced in C.B.-17 SCID mice by intraperitoneal (IP) in-
jection of CD45RBhigh cells (4 x 105) isolated from normal BALB/C mice 
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splenocytes (positive control group). Mice that received CD45RBhigh cells in 
combination with CD45RBlow cells were protected from disease development 
(negative control group). The treatment group received CD45RBhigh cells in 
combination with in vitro generated TregPMA cells (TregPMA cell treated 
group). The amount of TregPMA cells injected per mouse was 1.2 x 106.  
Monitoring development of colitis 
The primary read-out to assess the development of colitis was the body 
weight loss. Mice were weighed three times a week. Body weight loss was de-
termined by percentage of weight loss from base line body weight.  
After sacrifice, colon was excised and longitudinally divided into 2 parts both 
of which were rolled up: one was used for preparation of paraffin embedded 
samples while the other was snap frozen in liquid nitrogen. Disease activity 
index (DAI) was calculated by combining the scores applied to weight loss (0: 
<1%; 1: 1-5%; 2: 5-10%; 3: 10-15%; 4: >15%), stool consistency at sacrifice 
(0: normal; 1: loose droppings; 2: loose stools, colon filled with feces; 3: loose 
stool, feces only near caecum, 4: empty bowel) and rectal bleeding (0: nega-
tive; 2: positive; 3: gross bleeding) divided by three.      
Histology 
The half divided colon tissue was fixed in 4% paraformaldehyde and embed-
ded in paraffin. The colon tissue was cut in 5 µm sections and stained with 
haematoxylin and eosin for histological scoring. An experienced pathologist 
blinded to experiment inspected microscopically all sections and graded them 
on a scale 0 to 4 looking at: mononuclear and polymorphonuclear infiltrate, 
goblet cell depletion, crypt loss, epithelial hyperplasia, presence of ulcerations 
and manifestations of crypt abscesses.   
Cytokine analysis 
Frozen colon tissue was crushed with the use of CryoPrep™ System (Covaris) 
and resuspended in ice-cold PBS (pH 7.2) containing complete protease inhib-
itor (Roche). Homogenates were then centrifuged at 15000 x g for 5 min at 
C and the supernatants were stored at -80°C until the cytokine assay. Prior to 
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cytokine analysis total concentration of the protein in supernatants was deter-
mined with the use of Bradford assay (Biorad). Colonic tissue and plasma lev-
els of IL-1β, IL-6, IL-10, IL-17 and TNF-α were analyzed using a mouse cyto-
kine magnetic bead-based multiplex assay (Biorad) according to the manufac-
turer’s instructions. Additionally TGF-β levels were analyzed with Bio-Plex 
Pro TGF-β assay (Biorad) according to manufacturer’s instructions.  
Statistical analysis 
Data were analyzed statistically and graphed using Prism 5.0 (GraphPad Soft-
ware). Changes in mice weekly body weight, body weight at sacrifice, disease 
activity index (DAI), histological score and cytokine levels are shown as mean 
± standard deviation (SD) and analyzed by one-way ANOVA, followed by 
Bonferroni’s Multiple Comparison Test. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001   
Results 
CD4+CD25- T cells acquire a regulatory T cell phenotype through 
PMA/ionomycin/anti-CD3 mediated activation 
In order to generate regulatory T cells, CD4+CD25- cells from Balb/C mice 
were activated overnight on 96-well plate coated with anti-CD3. Subsequently 
PMA/ionomycin and IL-2 were added to the cell culture. After 5 days in cul-
ture, the cells were analyzed for their phenotype by flow cytometry. Between 
85.26% and 91.85% of the cultured cells were shown to up-regulate and co-
express the CD4 and CD25 markers (mean 91.4 ± 5.9%, n=3, Figure 1.A, C). 
The absence of PMA/ionomycin activation step on CD4+CD25- cells resulted 
in significant decrease in cell viability (data not shown) which confirms the 
necessity of additional activation with PMA/ionomyin.  
Additionally, we analyzed the expression of Foxp3, CTLA-4, GARP, ICOS 
and OX-40 markers which are known to be associated with a T regulatory cell 
phenotype and function [18-22]. All tested markers were found to be up-
regulated in ~30% of the CD4+CD25+ T cells after activation (a representa-
tive result is shown in Figure 1.D, Figure 2.A, B, C, D). 
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Similarly to previously reported data with iTreg cells generated in vitro [23], the 
cellular level of Foxp3 expression in the cells activated with PMA/ionomycin/
anti-CD3 appears to be low (Figure 1.B, D).  
We will refer to the cells treated with PMA/ionomycin/anti-CD3 activation 
(iTreg cell population) as ‘TregPMA’ cells. 
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TregPMA cells ameliorate the disease phenotype in a colitis transfer 
mouse model 
IBD was induced in C.B-17 SCID mice by transfer of CD45RBhigh cell popu-
lation from BALB/C mice (positive control group) and was prevented by co-
transfer of CD45RBlow cell population (negative control group) [24-27]. 
The read-out parameters of the development and progression of the colitis in 
the transfer mouse model are body weight loss and inflammation of the intes-
tinal tissue. 
The positive control group developed colitis and presented a relative decrease 
of initial body weight 86.88 ± 5.06% (n=9) at sacrifice which was significantly 
lower than the negative control that reached 110 ± 3.29% (n=10) of the initial 
body weight. The TregPMA cell treatment (injection of TregPMA cells to-
gether with CD45RBhigh cells) reduced significantly the body weight loss to 
99.18 ± 7.17% (n=10) as compared to the positive control group (Figure 
3.A, B).    
The Disease Activity Index (DAI), which is an indicator of colonic inflamma-
tion, reflecting weight loss, stool consistency and presence of rectal bleeding 
was determined at sacrifice. The DAI was significantly lower in mice treated 
with TregPMA cells (1.18 ± 0.55) when compared to the positive control 
group (2.04 ± 0.35), confirming the amelioration of the disease phenotype 
(Figure 3.C). 
Intestinal inflammation was further determined by histopathological analysis 
of colon tissue post mortem which includes evaluation of mononuclear and 
polymorphonuclear cell infiltrate, goblet cell depletion, loss of crypts, epitheli-
al hyperplasia and manifestations of ulcerations and abscesses [24-27].  
A significant reduction of inflammation was observed in the colon tissue of 
the TregPMA cell treated mice when compared to the positive control group 
(Figure 3.D). The spread of intestinal inflammation was less extensive and no 
ulcerations were observed in the TregPMA cell group (Figure 4.B) which was 
similar to the negative control group (Figure 4.A) while in the diseased con-
trol group they were commonly present (Figure 4.C). 
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Proinflammatory cytokine production in colon and in plasma of   
TregPMA cell treated mice is reduced 
We next examined the influence of TregPMA cell treatment on the produc-
tion of pro-inflammatory cytokines IL-6, IL-1β and TNF-α that have been 
previously described to be increased in CD45RB transfer colitis mouse model  
[28, 29]. The level of IL-10 and TGF-β that have been shown to have a regu-
latory effect in experimental colitis were also analyzed [30, 31]. Additionally 
the level of IL-17 cytokine that have been described to have both pro- and 
anti-inflammatory effect in IBD was measured [30, 32-35].   
The level of IL-6 was found to be decreased in TregPMA cell treated group in 
both colon homogenates and plasma at the day of sacrifice when compared to 
the positive control group (Figure 5.A, D). IL-1 β level was also found to be 
reduced after TregPMA cell treatment in colon homogenates but this decrease 
was not reflected in plasma (Figure 5.B, E).  
Elevated levels of IL-17 were found in colon tissue homogenates of TregPMA 
cell treated mice as well as in positive control group. However, the TregPMA 
cell treated group had higher level of colonic IL-17 than the positive control 
(Figure 5.C). No significant difference between groups was observed in the 
levels of IL-17 expression in plasma (Figure 5.F). 
TNF-α, IL-10 and TGF-β levels in both colon homogenates and plasma 
showed no significant differences between groups (data not shown).      
Discussion 
In this article we describe the generation of iTreg cells (TregPMA cells) in vitro 
from CD4+CD25- cells by PMA/ionomycin/anti-CD3 activation based meth-
od. Several other groups have explored different strategies to generate iTreg 
from naive T cells in vitro, including use of TGF- β, all-trans-retinoic acid and 
the recently discovered regulatory cytokine IL-35 [36, 37]. However, all these 
methods are more or less impeded with their own limitations [16]. Therefore, 
there is need for improvement in this field and our group designed and ex-
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plored a new method of in vitro iTreg cells (TregPMA) generation which we 
report in this manuscript.       
Mechanistically, PMA/ionomycin provides a potent stimulation allowing us to 
bypass the T cell receptor activation essential for Treg cell development and it 
prevents the emergence of CD4-CD8+ cells in the culture [17]. PMA activates 
protein kinase C [38] while ionomycin is a Ca2+ mobilizing agent [39]. This 
combination has been shown to up-regulate CD25 on T lymphocytes [17] and 
a high CD25 expression is a marker of the Treg cell phenotype [40]. Addition-
ally, it was demonstrated that Ca2+ signaling is required for the development 
and function of Treg cells [41, 42]. Therefore we expected that raising the in-
tracellular levels of Ca2+ in naive T cells using ionomycin would have a syner-
gistic effect with PMA in starting a regulatory developmental program in 
CD4+CD25- cells. Additionally a low dose of IL-2 was used in cell culture 
since IL-2 is important for Treg cell homeostasis and maintaining their sup-
pressive survival program [43] while anti-CD3 which is also present in the cell 
culture has been shown to maintain and expand Treg cells [44], however use 
of only anti-CD3 and IL-2 for in vitro CD4+CD25- cell stimulation resulted in 
low cell viability and poor regulatory markers expression which indicates that 
additional stimulation with PMA/ionomycin is needed. 
The TregPMA cells up-regulate CD25, and ~30% of the CD4+CD25+ T cells 
up-regulate CTLA-4, GARP, ICOS, OX-40 and Foxp3 which are important 
markers associated with regulatory cell phenotype and function [18-22, 45, 
46]. Interestingly, the level of Foxp3 expression in TregPMA cells is quite low. 
Although Foxp3 expression is considered to be a main characteristic of Treg 
cells, Treg cells are recognized to be a heterogeneous cell population. Espe-
cially, it has been reported that CD4+CD25+ Foxp3- cell population also can 
present regulatory function in vitro and in vivo [23]. 
The functionality of the TregPMA cells has been demonstrated in vivo by their 
potential to ameliorate the disease phenotype in a CD45RB transfer colitis 
mouse model. It cannot be fully excluded that the amelioration of the disease 
phenotype observed in the group of mice treated with the TregPMA cells 
does not partially involve cell types, other than regulatory, present in the cell 
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suspension injected. Indeed, high numbers of CD45RBhigh cells (6 x 106/
mouse) have been shown to reduce the severity of the disease in a mouse 
model of colitis [47]. However, in our study, the total number of cells injected 
(1.2 x 106/mouse) was significantly lower and the amelioration of the severity 
of the disease was observed in all of the treated animals (n = 10) against 3 out 
of 5 in the mentioned study. All together, these data suggest that the observed 
protective effect is mostly related to TregPMA cells. 
The disease amelioration was accompanied by a decrease of the pro-
inflammatory IL-1 β levels in the colon tissue which reflect the severity of 
experimental colitis [28]. Such a decrease in IL-1 β was previously reported by 
Hirano and Kudo after treatment of CD45RB transfer colitis mouse model 
with both dexamethasone and anti-tumor necrosis factor-α (anti-TNF-α).  
IL-1 β stimulates the production of the pro-inflammatory cytokine IL-6 [48] 
which has been described to be up-regulated in mouse model of IBD [49] and 
in human ulcerative colitis or Crohn’s disease patients [50]. Simultaneously 
with the decrease of IL-1β in our study, IL-6 levels were found to be reduced 
in both colonic homogenates and plasma samples after treatment with   
TregPMA cells.  
The concentration of IL-17 was found to be more elevated in colon homoge-
nates of TregPMA cell treated mice than in the positive control group. Alt-
hough the role of this cytokine in the initiation or pathogenesis of IBD is con-
troversial, a protective function of IL-17 in the gut of CD45RB transfer colitis 
model has been previously noted [30, 33, 51]. Several groups have reported 
that both IL-17-/- CD45RBhigh and IL-17R-/- CD45RBhigh cells induce a 
more aggressive disease phenotype than wild type CD45RBhigh cells [30, 51]. 
Accordingly, our results show that an increased IL-17 level also correlated 
with less severe intestinal inflammation and lack of ulcerations.   
IL-10 and TGF- β cytokine level in both mouse plasma and colon homoge-
nates show no significant differences between experimental groups at the time 
of experiment termination (week 7). However, it does not exclude the possible 
influence of those cytokines on prevention of the colitis induction at earlier 
time point. 
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The cells that have been found mostly responsible for pathogenesis of 
CD45RB transfer model of IBD are Th1 cells. Recently it has been shown 
that IL-17 blocks the Th1 cell development in vivo via IL-17R on naive CD4+ 
T cells [30, 51]. In the TregPMA cell treated group we also observe elevated 
level of IL-17 which correlates with disease amelioration. IL-17 can be pro-
duced by many types of cells among which are also T regulatory cells [52]. 
Therefore we are hypothesizing that in vivo disease amelioration by TregPMA 
cells is IL-17 mediated. As follow-up to this study,  physiological relevance of 
TregPMA cells and their exact molecular mechanism of action needs to be 
determined. 
Conclusions 
Induced regulatory T cells are promising tools for therapeutic applications in 
IBD [49] as well as in other autoimmune disorders and are of great scientific 
interest and many techniques to generate inducible Treg cells from naive T 
cells have been developed and described [8, 36, 37, 54, 55]. Different activa-
tion methods to generate iTreg cells result in iTreg cells that are heterogene-
ous in phenotype. The in vitro PMA/ionomycin/anti-CD3 activation of 
CD4+CD25- T cells has proven to generate functional iTreg cells (TregPMA 
cells) but the in vivo physiological relevance of TregPMA cell signaling needs 
to be further investigated. 
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Abstract 
Aim 
To explore the anti-inflammatory potential of adeno-associated virus-
mediated delivery of Tregitope 167 in an experimental colitis model.  
Methods 
The Trinitrobenzene sulfonate (TNBS) model of induced colitis was used in 
Balb/c mice. Subsequently after intravenous adeno-associated virus-mediated 
Tregitope delivery, acute colitis was initiated by intra-rectal administration of 
1.5 mg TNBS in 40% ethanol followed by a second treatment with TNBS 
(0.75 mg in 20% ethanol) 8 days later. Control groups included mice not treat-
ed with TNBS (healthy control group) and mice treated by TNBS only 
(diseased group). At the time of sacrifice colon weight, the disease activity 
index and histology damage score were determined. Immunohistochemical 
staining of the colonic tissue was performed to assess the cellular infiltrate and 
the presence of transcription factor Forkhead Box-P3 (Foxp3). Thymus, mes-
enteric lymph nodes, liver and spleen tissue were collected and the corre-
sponding lymphocyte populations were further assessed by flow cytometry 
analysis for the expression of CD4+ T cell and regulatory T cell associated 
markers. 
Results 
The Tregitope 167 treated mice gained an average of 4% over their initial 
body weight at the time of sacrifice. In contrast, the mice treated with TNBS 
alone (no Tregitope) developed colitis, and lost 4% of their initial body weight 
at the time of sacrifice (P value <0.01). The body weight increase that had 
been observed in the mice pre-treated with Tregitope 167 was substantiated 
by a lower disease activity index and a decreased colon weight as compared to 
the diseased control group (P value <0.01 and <0.001 respectively). Immuno-
histochemical staining of the colonic tissues for CD4+ showed that inflamma-
tory cell infiltrates were present in TNBS treated mice with or without admin-
istration with Tregitope 167 and that these cellular infiltrates consisted mainly 
of CD4+ cells. For both TNBS treated groups CD4+ T cell infiltrates were 
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observed in the sub-epithelial layer and the lamina propria. CD4+ T cell infil-
trates were also present in the muscularis mucosa layer of the diseased control 
mice, but were absent in the Tregitope 167 treated group. Numerous Foxp3 
positive cells were detected in the lamina propria and sub-epithelium of the 
colon sections from mice treated with Tregitope 167. Furthermore, the Foxp3 
and glycoprotein A repetitions predominant (GARP) markers were signifi-
cantly increased in the CD4+ T lymphocyte population in the thymus of the 
mice pre-treated with adeno-associated virus serotype 5 (cytomegalovirus 
(CMV) promoter-Tregitope 167), as compared to lymphocyte populations in 
the thymus of diseased and the healthy control mice (P value <0.05 and 
<0.001 respectively). 
Conclusion 
This study identifies adeno-associated virus-mediated delivery of regulatory T-
cell epitope 167 as a novel anti-inflammatory approach with the capacity to 
decrease intestinal inflammation and induce long-term remission in IBD. 
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Introduction 
Inflammatory Bowel Diseases (IBD) are inflammatory diseases that affect 
mostly young adults [1, 2]. Although the precise pathogenesis has not been 
identified, it is generally accepted that IBD result from inappropriate mucosal 
immune system responses against intestinal flora and other luminal antigens [3
-5]. IBD are associated with a reduction in quality of life [6-8] and no curative 
treatments are available.  
Despite the fact that novel treatment strategies, including tumor necrosis fac-
tor (TNF)-neutralizing antibodies, have greatly expanded the therapeutic ar-
mamentarium, these therapeutics do not prevent complications in IBD and 
many patients still have to undergo surgery [9]. New treatment strategies that 
would prevent the initiation of inflammation and enable long-term remission 
would improve the lives of millions of individuals who are affected by IBD 
world-wide [10, 11]. 
Recently, biological therapies that target immune pathways have emerged as a 
new therapeutic approach for the treatment of immune-mediated diseases. 
They include administration of monoclonal antibodies against inflammatory 
cytokines [12] and those that influence immune responses such as certain 
small molecules, Helminths and stem cells [10, 13, 14]. Since IBD are immune
-mediated diseases, these biological therapies are highly promising treatment 
approaches and have the potential to achieve mucosal tolerance and long-term 
remission in IBD [10, 12-14]. Here, we introduce regulatory T-cell epitopes 
(Tregitopes) [15, 16] as novel biological agents that could create new possibili-
ties for the regulation of inflammation and postulate that Tregitopes, delivered 
by adeno-associated virus (AAV), could be developed as a new therapeutic 
modality for the treatment of IBD.  
Tregitopes are a set of putative regulatory T cell epitopes present in the immu-
noglobulin G molecule, which have been identified by using computational 
epitope mapping [15, 16]. Tregitope sequence 167 (Tregitope 167) and an ad-
ditional sequence (Tregitope 289) were synthesized and shown to bind to mul-
tiple Major Histocompatibility complex (MHC) class II molecules and to sup-
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press immune response when co-administered with an antigen. Tregitopes 167 
and 289 were also shown to expand natural occurring regulatory T (nTreg) 
cells and to induce a regulatory phenotype and function in peripheral T (iTreg) 
cells [15, 16]. Harnessing the potential of Treg cells activated or induced by 
Tregitopes to regulate pathological immune responses in IBD may reduce the 
requirement for systemic immunosuppressive therapies. However, the use of 
immunomodulatory peptides in clinical applications for IBD so far have 
shown that the in vivo delivery of these peptides for therapeutic purposes is 
hindered by difficulties in obtaining sufficient and stable peptide concentra-
tions [17-19]. Therefore, novel means for stable delivery of regulatory peptides 
have to be explored. Adeno-associated viruses (AAV) present a good safety 
profile and have been shown to be effective as gene delivery vectors in the 
clinic for the treatment of a broad range of diseases [20-22]. Therefore, AAV-
mediated delivery represents an attractive approach to deliver the immuno-
modulatory Tregitope peptides.  
In the present study, the potential of AAV-mediated gene therapy for the 
therapeutic delivery of Tregitope 167 was explored. Systemic AAV-mediated 
administration of Tregitope 167 was shown to ameliorate the clinical and histo
-pathological severity of Trinitrobenzene sulfonate (TNBS) induced inflam-
matory colitis in mice. Hence, AAV-mediated delivery of regulatory T-cell 
epitopes appears to be a promising novel therapeutic approach for the treat-
ment of IBD and could represent an alternative or adjunct to the use of im-
munosuppressive drugs. 
Materials and methods 
AAV vector production and characterization 
Mouse Tregitope cDNA was synthesized (Integrated DNA Technologies, 
IDT, Inc) according to the published corresponding sequence [15, 16] and 
cloned into the plasmid pCH110 [23] under the control of the cytomegalovi-
rus (CMV) promoter. The Woodchuck hepatitis virus post-transcriptional en-
hancer (WPRE) was incorporated behind the Tregitope 167 cDNA to further 
optimize gene expression [24]. The AAV vector, AAV5 (CMV-Tregitope 167) 
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was produced according to a technology adapted from A. Negrete and R.M. 
Kotin [23]. The AAV batch was purified with an AVB sepharose column us-
ing the ÄKTA explorer system (GE Healthcare). After purification, the con-
centration of AAV vector genomes copies (gc/ml) was determined at 9 x 
1013gc/ml by Taqman qPCR amplification. The biological infectivity of AAV5 
(CMV-Tregitope 167) was demonstrated in vitro by PCR amplification of the 
“CMV-Tregitope 167” DNA fragment (product size 402bp) on DNA isolated 
from HEK293T transduced with AAV5 (CMV-Tregitope 167). Primers de-
signed and synthesized for Tregitope 167 and the CMV promoter were used. 
Induction of colitis and study design 
Balb/c mice (males, age 6-8 weeks) were obtained from Harlan Laboratories, 
the Netherlands. The experimental protocol was approved by the ethical com-
mittee for animal welfare of the AMC (Academic Medical Center, Amsterdam, 
the Netherlands). Colitis was induced in mice by administration of TNBS 
(Trinitrobenzene sulfonate, TNBS, Sigma-Aldrich), as described previously 
[25]. The general procedure is summarized in Figure 1. 
Mice were injected intravenously with either PBS or AAV5 (CMV-Tregitope) 
10 days before acute colitis was initiated by intra-rectal administration of 1.5 
mg TNBS in 40% ethanol. Consecutively, a second TNBS treatment (0.75 mg 
in 20% ethanol) was done 8 days after the first TNBS treatment as described 
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precedently [25]. Mice not treated with TNBS (healthy control group) and 
mice treated with TNBS only (diseased control group) were used as references 
to monitor colitis development. A concomitant sham AAV control vector was 
not used in this study as this control has been shown to be equivalent to saline 
control [26, 27]. Even though AAV-mediated gene transfer leads to the devel-
opment of neutralizing antibodies against the vector capsid [28], preventing 
vector re-administration, no inflammatory responses against the AAV capsid 
were documented in in vivo gene transfer mice models using AAV vectors [27, 
29].   
Assessment of Inflammation 
The body weights of the mice were recorded daily, and wasting disease pro-
gression was expressed by the percentage of weight loss as compared to body 
weight at the day of initiation of TNBS treatment (Figure 2). Animals were 
withdrawn from the study when their weight loss was >25% of their original 
body weight. At the time of sacrifice, colons were collected and presence of 
loose stool and visible fecal blood was assessed. 
At the time of sacrifice, a composite score (disease activity index, DAI) was 
established as described previously [25]. Body weight loss was scored on a 
scale of 0–4 (0, <1%; 1, 1%-5%; 2, 5%-10%; 3, 10%-15%; 4, >15%). Loose 
stool was scored on a scale of 0–4 (0, normal; 1, loose droppings; 2, loose 
stools, colon filled with feces; 3, loose stool, feces only near cecum; 4, empty 
bowel). Visible fecal blood was scored on a scale of 0–4 (0, negative; 2, posi-
tive; 4, gross bleeding). The DAI consists of a combination of body weight 
loss, loose stool and visible fecal blood scores divided by 3 as described previ-
ously [25]. 
Colon tissue weights were recorded and used as an indicator of disease-related 
intestinal wall thickening. Increased colon weight has been shown to correlate 
with increased colon inflammation [25]. Colons were first divided longitudi-
nally into two parts: one part was immediately frozen in liquid nitrogen for 
protein extraction and cytokine level determination, while the second part was 
stored in formalin and embedded in paraffin for immunohistological evalua-
tion. Blood was collected by orbital puncture immediately following sacrifice 
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and plasma was separated by centrifugation (5000 rpm for 5 min). Plasma 
samples were stored at −80°C until analysis. 
Histological analysis 
Colonic segments were fixed in 10% formalin overnight and thereafter stored 
in 70% ethanol before embedding in paraffin. Tissue sections (7 μm thick) 
were stained with haematoxylin for histology scoring. The histology damage 
score was calculated using the following criteria: percentage of area involved, 
number of follicle aggregates, edema, fibrosis, erosion/ulceration, crypt loss, 
and infiltration of mononuclear and polymorphonuclear cells as described 
previously [30]. The percentage of area involved and crypt loss were scored on 
a scale of 0–4 (0, normal; 1, <10%; 2, 10%; 3, 10%–50%; and 4, >50%). Ero-
sions were defined as 0 if the epithelium was intact, 1 if the lamina propria 
was involved, 2 if ulcerations involved the submucosa, and 3 when ulcerations 
were transmural. The severity of the other parameters was scored on a scale of 
0–3 (0, absent; 1, weak; 2, moderate; and 3, severe) [30]. A certified 
pathologist scored all the tissue sections (blinded analysis). 
Immunohistochemistry 
Colon tissues sections of 7 μm were aceton-fixed and stained with rat anti-
mouse (rαm) CD4 (1:100, BD550278), rαm CD8a (1:50, BD550281), rαm 
CD19 (1:50, BD550284), rαm Foxp3 (1:100, eBiosciences14-5773-82) and 
rαm F4/80 (1:500). Prior to anti-rat biotin conjugated secondary antibody 
(1:50, BD51-7605kc) and streptavidin-HRP (BD) incubations, endogenous 
peroxidases were blocked by incubation with 0.3% H202 for 20 minutes. After 
5 min of DAB staining (BD), the sections were counter-stained with haema-
toxylin, dehydrated and mounted in entallan. 
Flow cytometry 
Thymus, mesenteric lymphoid nodes, liver and spleen tissue were collected 
upon sacrifice. Cell suspensions obtained from each of the tissue samples 
were prepared using 40 µm cell strainers (BD Biosciences) and stained for T 
cell surface markers CD4 (clone RM4-5, eBioscience), CD8 (Clone 53-6.7, 
Miltenyi) and Treg cell surface markers GARP and CD25 (clone YGIC86 and 
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clone PC61.5 respectively, both eBioscience) as well as for the intracellular 
Treg cell marker Foxp3 (clone FJK16, eBioscience). The analysis was per-
formed by flow cytometry (FACSCalibur, BD Biosciences).  
Statistical analysis 
The results are presented as means (+/- standard deviation (SD) or standard 
error of the mean (SEM), where appropriate). Statistical analyses were per-
formed using Prism 5.0 (GraphPad). Data were analyzed using a 1 way ANO-
VA, followed by Dunn’s post hoc test for multiple comparisons. 
Results 
We investigated the potential for AAV5-mediated delivery of regulatory T-cell 
epitopes to prevent the development of TNBS induced colitis. Mice treated 
intra-rectally with TNBS in ethanol developed a severe illness as reflected in 
the progressive body weight loss over time and an increase in disease activity 
index, histology damage score and mucosal inflammatory parameters at the 
time of sacrifice. 
Tregitope 167 delivery protects against TNBS colitis development 
Development of colitis in the TNBS mice model is strongly associated with 
wasting disease [31]. Daily weight determination is therefore important to de-
termine colitis severity and is indicative of differences in colitis development 
between experimental groups [31]. Animals were withdrawn from the study 
when their weight loss was >25% of their original body weight.  
The body weight of the mice was monitored daily after the first TNBS treat-
ment as an indication of the severity in the colitis development between ex-
perimental groups (Figure 2). TNBS treated mice that were pre-administered 
with Tregitope 167, showed a body weight that increased over time and was 
comparable to the weigh gain of untreated healthy control mice (Figure 2). 
The Tregitope 167 treated mice gained an average of 4% over their initial 
body weight at the time of sacrifice (Figure 3.A). In contrast, the mice treated 
with TNBS alone (no Tregitope) developed colitis, and lost 4% of their initial 
body weight at the time of sacrifice (Figure 3.A).  
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Increases in colon weight, as well as in the disease activity index are both in-
dicative of colonic inflammation and were determined at the time of sacrifice. 
The body weight increase that had been observed in the mice pre-treated with 
Tregitope 167 was substantiated by a lower disease activity index (Figure 3.B) 
and a decreased colon weight (Figure 3.C) as compared to the diseased con-
trol group (P value <0.01 and <0.001 respectively). 
The histology damage score was performed on HE stained tissue sections. 
The score was calculated using the following criteria: percentage of area in-
volved, number of follicle aggregates, edema, fibrosis, erosion/ulceration, 
crypt loss, and infiltration of mononuclear and polymorphonuclear cells. The 
histological scoring showed that the AAV5 (CMV-Tregitope 167) pre-treated 
mice presented a decreased severity of colitis as compared to the diseased 
control group (Figure 3.D) as a result of lower levels of inflammation, namely 
decreased cellular infiltrations, little crypt loss and the absence of erosions and 
ulceration (Figure 4).  
The TNBS induced colitis model is characterized by the local infiltration of 
CD4+ T cells in the intestinal mucosa [32]. Immunohistochemical staining of 
the colonic tissues for CD4+ showed that, at the day of sacrifice, inflammatory 
cell infiltrates were present in TNBS treated mice with or without administra-
tion with Tregitope 167 and that these cellular infiltrates consisted mainly of 
CD4+ cells. For both TNBS treated groups CD4+ T cell infiltrates were ob-
served in the sub-epithelial layer and the lamina propria. CD4+ T cell infil-
trates were also present in the muscularis mucosa layer of the diseased control 
mice, but were absent in the AAV5 (CMV-Tregitope 167) treated group 
(Figure 5).   
Increase of regulatory markers expression in the intestinal mucosa and 
thymus of mice administered with Tregitope 167 
The reported ability of Tregitopes to both activate and induce Treg cells led us 
to further assess the presence of Treg-cell associated markers in the colonic 
tissues.  
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Colon tissues were prepared and the presence of transcription factor Foxp3 
was assessed by immunohistochemistry, so as to determine whether regulatory 
T cells were present in the peri-colonic infiltrates [33]. Numerous Foxp3 posi-
tive cells were detected in the lamina propria and sub-epithelium of the colon 
sections from mice treated with Tregitope 167 (Figure 6). Foxp3 positive 
cells were absent or sporadic in the colon of healthy and diseased control mice 
(Figure 6). 
Thymus, mesenteric lymph nodes, liver and spleen tissue were collected at the 
time of sacrifice and the corresponding lymphocyte populations were further 
assessed by flow cytometry analysis for the expression of the CD4 T cell sur-
face marker and the Treg cell associated markers Foxp3 [34], CD25 [35] and 
GARP [36, 37]. The Foxp3 and GARP markers were significantly increased in 
the CD4+ T lymphocyte population in the thymus of the mice pre-treated 
with AAV5 (CMV-Tregitope 167), as compared to lymphocyte populations in 
the thymus of diseased and the healthy control mice (P value <0.05 and 
<0.001 respectively, Figure 8). CD4+ thymic lymphocyte population (mean ± 
SD, 11% ± 2%, n=6) co-expressed Foxp3 and GARP in the thymus of AAV5 
(CMV-Tregitope 167) pre-treated mice as compared to the thymic lymphocyte 
population of diseased (mean ± SD, 7% ± 3%, n=6) and the healthy control 
groups (mean ± SD, 6% ± 2%, n=9), respectively (Figures 7). Both the rela-
tive and absolute number of Foxp3 expressing T cells were expanded in the 
thymus after AAV5 (CMV-Tregitope 167) pre-treatment (Figure 9). No sig-
nificant differences in the expression of Foxp3 and GARP in the lymphocyte 
populations of the mesenteric lymph nodes, liver and spleen were identified. 
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Discussion 
Curative treatment approaches for Crohn's disease and ulcerative colitis repre-
sent a significant unmet medical need. Regulatory T (Treg) cells are key play-
ers in maintaining peripheral tolerance, preventing autoimmune diseases and 
limiting chronic inflammation [33, 38]. Therefore, novel strategies that aim for 
therapeutic tolerance induction and leverage Treg cells are currently being ex-
plored [39]. In the present study, the potential for AAV-mediated delivery of 
an immunomodulatory peptide (Tregitope 167) was investigated.  
In this study, we demonstrate that the systemic AAV-based delivery of Tre-
gitope 167 has the potential to prevent the development of fulminant colitis in 
a TNBS-induced model of IBD. Tregitope 167 was used in our study as its 
binding affinity for the MHC molecule in Balb/c mice is superior to Tregitope 
289 (De Groot, manuscript submitted for publication). The significant de-
4 
Tregitope 167 ameliorates experimental colitis 
100 
 
crease of colonic inflammation in the Tregitope 167 pre-treated mice was re-
flected in an overall weight gain and substantiated by a decreased disease ac-
tivity index, colon weight and histology damage score at the time of sacrifice. 
Additionally, there was less mucosal inflammation in the AAV (CMV-
Tregitope 167) pre-treated mice. This therapeutic benefit corresponded with 
increases in the relative number of T cells expressing regulatory T cell markers 
in the colon tissues and among thymic lymphocytes of the Tregitope 167-
treated mice. 
IBD patients do not present defects in regulatory T cell function or phenotype 
[40-42] and by consequence are more likely to benefit from therapies aiming 
at inducing and expanding Treg cells than patients affected by other autoim-
mune diseases. Tregitope 167 has the potential to both activate nTreg cells 
and induce iTreg cells [15, 16] and may be suitable as a novel therapeutic agent 
for IBD. However, the use of immunomodulatory peptides in clinical applica-
tions for IBD has been hindered by difficulties associated with the systemic 
delivery of the therapeutic peptides in sufficient quantity and concentration to 
the target tissues [17-19]. AAV has proven to be both effective and safe as a 
gene therapy delivery vector in the clinic [20-22]. Therefore, AAV-mediated 
delivery of Tregitopes was explored in this study. The AAV serotype 5 
(AAV5) was used since pre-existing immunity to AAV5 in humans has been 
shown to be low [28, 43]. Our data demonstrate that AAV5-mediated delivery 
may be an efficient approach for stable administration of Tregitopes in vivo. 
Further studies will need to be performed to determine the duration of the 
immunological tolerance that is evoked by induction and activation of Treg 
cells.  
Regulatory T (Treg) cells are considered to be essential in the counter-
regulation of inflammatory reactions and Foxp3 is considered as a marker of 
the regulatory phenotype [34, 44, 45]. Staining for Foxp3 in mice pre-treated 
with Tregitope 167 revealed the presence of Foxp3 positive cells in the lamina 
propria and sub-epithelium of the colon sections. Additionally, expression of 
both Foxp3 and GARP were increased in the thymic CD4+ T lymphocyte 
population in mice pre-treated with AAV5 (CMV-Tregitope 167), indicating 
an increase in activated regulatory T-cells [34, 36, 37, 44, 45]. The presence of 
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higher numbers of activated regulatory T cells corresponded with the preven-
tion of fulminant intestinal inflammation in vivo in this TNBS model of IBD.  
No increase in the Treg cell populations was observed in the mesenteric 
lymph nodes, liver and spleen in the current study. We hypothesize that this 
could be due to the duration of the experiment and the timing of the Treg cell 
evaluation. In other mouse models such as the model of spontaneous enceph-
alomyelitis, the de novo generation of Treg cells was initiated intrathymically, 
and was followed by Foxp3 induction in peripheral tissue at later time points 
[46]. 
Tregitopes are T cell epitopes naturally located in immunoglobulins that bind 
to multiple MHC Class II alleles and induce Treg cell responses. We have 
demonstrated that antigen presenting cells (APCs) present Tregitopes to 
nTreg cells, engage feedback mechanisms promoting a tolerogenic APC phe-
notype, induce Treg cell expansion, and modulate antigen-specific effector T 
cell responses (Cousens and De Groot, manuscript submitted for publication). 
Proportions of APC expressing MHC II, CD80, and CD86 are suppressed, 
consistent with reported effects of Intravenous immunoglobulin (IVIG) [47] 
and of the immunoglobulin (Ig) G-derived peptide hCDR1 [48]. The basic 
mechanism of Tregitope tolerance induction is currently proposed to be as 
follows: 1) APC present Tregitopes to nTreg cells, 2) nTreg cells are activated 
to proliferate, 3) nTreg cells provide tolerogenic feedback signals to APC, 
modulating the APC phenotype, and 4) nTreg cells and tolerogenic APC to-
gether suppress antigen-specific T cell responses (Cousens and De Groot, 
manuscript submitted for publication). 
A limitation of the colitis model used in this study was the acute necrotizing 
enterocolitis, occurring in the first 3 days after the first TNBS treatment, a 
presentation of disease which is unrelated to IBD [25]. Therefore the surviv-
ing number of mice, included in the analysis was lower than anticipated, 
which, for some analysis, conflicted with statistical analysis of the data. As a 
consequence, a large variability in the colon mucosa cytokines levels was ob-
served after TNBS induced experimental colitis and prevented an accurate 
analysis of those parameters. Therefore, further development of AAV mediat-
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ed delivery of Tregitope 167 in different experimental models of inflammatory 
disease will be necessary to confirm the obtained results. 
In summary, our data provide preliminary evidence supporting the potential 
use of AAV-based Tregitope delivery as a therapy for the treatment of IBD. 
Further investigations will permit to define the mechanism by which          
Tregitope exert their immune regulatory properties, the duration of the effect, 
the ability of Tregitopes to reduce disease that has already been established 
and their eventual impact on systemic immunity.  
Overall, this study identifies AAV-mediated delivery of regulatory T cell 
epitope 167 as a novel anti-inflammatory approach with the capacity to de-
crease intestinal inflammation and induce long-term remission in IBD. 
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I AAV vectors 
Adeno-associated (AAV) vectors are used to achieve therapeutic gene delivery 
for the treatment of genetic and chronic disorders. Recombinant AAV vectors 
contain an expression cassette with a transgene of choice flanked by two non-
coding viral inverted terminal repeats (ITR’s) enclosed in a capsid which is 
composed of three proteins: VP1, VP2 and VP3. When AAV enters the cell, 
its genome is converted into double-stranded, transcriptionally active DNA, 
which predominantly persists in a non-integrated episomal form [1, 2]. These 
vectors efficiently transduce a wide variety of tissues and can provide the long 
term expression of the delivered gene after a single administration. Important-
ly, AAV vectors have not been associated with any pathology in humans and 
are replication-defective. AAV-based gene delivery has been successfully em-
ployed in treatment of genetic disorders in preclinical studies as well as in clin-
ical trials [3-6]. The clinical studies included hundreds of patients and indicate 
an excellent safety record of AAV vectors for gene therapy in humans. The 
different safety aspects of AAV for the use in humans have recently been 
summarized elsewhere [7]. Immune responses have been assessed in clinical 
trials by measuring systemic and local cytotoxic reactions as well as neutraliz-
ing antibodies (NAB) against AAV and/or the expressed therapeutic protein 
[3, 5, 8-17]. The immunogenicity data reported so far show that immune re-
sponses against AAV capsid proteins can vary and are influenced by the target 
organ, route of delivery and dosing schedule.  
 
II Cellular immune responses against AAV vectors 
The first observation of a cellular immune response induced by AAV gene 
therapy occurred in patients with Hemophilia B who were treated with an 
AAV2 vector to deliver human coagulation factor IX [14, 18]. In this study, a 
cell mediated immune response to AAV2 capsid was reported, which was 
measured in parallel with a loss of transgene expression. Similar observations 
were reported in a more recent clinical study with AAV serotype 8 for FIX 
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delivery to the liver of Hemophilia B patients, when two patients receiving the 
highest vector dose required a short course of glucocorticoids which normal-
ized serum aminotransferase levels and prevented the loss of transgene ex-
pression [6]. Whereas in patients with Hemophilia B a correlation between the 
induction of a CD8+ T cell response towards the AAV capsid proteins and a 
loss of transgene expression was observed, this does not seem to be an issue 
in case of the intramuscular AAV vector delivery. In a clinical study in patients 
with α-1 antitrypsin deficiency in which the gene for α-1 antitrypsin was deliv-
ered by an AAV1 capsid, cellular immune responses were found against the 
capsid proteins from day 14 on in all subjects. However, the functional activi-
ties of those T cells, as well as the biological effects thereof are not clear since 
the expression of the transgene was sustained at sub-therapeutic levels in all 
subjects. These data suggest that the cellular immune responses to the AAV 
capsid did not eliminate the transduced cells [8]. Similarly, systemic and local 
cellular immune responses induced by intramuscular injection of alipogene 
tiparvovec did not impact on clinical efficacy and safety [4]. 
 
III Managing humoral immune responses against AAV 
capsid 
A major challenge for successful tissue targeting of AAV vectors in patients is 
the presence of circulating neutralizing antibodies (NAB) against AAV vector 
capsid. There is little knowledge about the antigenic structures of AAV cap-
sids and how exactly they interact with the antibodies that are raised against 
them. Nevertheless, antigenic epitopes have been identified and described for 
AAV capsids of serotypes 2 and 8 [19-21].  
NAB can be present in the patient’s blood prior to therapy due to naturally 
acquired infections with the wild type AAV virus (pre-existing NAB) pre-
existing NAB against AAV are currently an exclusion criteria for participation 
in clinical trials that use AAV vectors. This is a major problem, because, de-
pending on the AAV serotype, the reported prevalence of serotype-specific 
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pre-existing anti-AAV NAB in humans is considerable and there is a signifi-
cant difference between AAV serotypes (Figure 1) [22]. 
 
  
Figure 1. Adapted from Boutin et al. (Human Gene Therapy 2010). Prevalence of neutralizing 
factors in serum against AAV types 1, 2, 5, 6, 8 and 9, n indicates the number of serum samples 
tested.  
Anti-AAV NAB are also formed after first administration of AAV vector gene 
therapy. Those NAB may reach high titers and have been reported to persist 
after treatment.  
Although AAV-mediated expression generally is long-lived, re-administration 
may be necessary, during the lifetime of the patient, the naturally occurring 
turnover of cells might lead to loss of AAV transduced cells that episomally 
express DNA encoding the therapeutic protein, resulting in a decrease of the 
production of therapeutic protein. Repeated AAV treatment might also be 
needed if the initial treatment does not result in expression of sufficient thera-
peutic protein. In both cases, re-administration of the same AAV is thought 
not to be possible due to the presence of circulating NAB formed after the 
first administration. Those antibodies totally block the transduction and no 
efficacy of the treatment can be observed [1, 23].  
 In order to address these issues, numerous approaches have been explored to 
overcome or circumvent humoral immune responses directed at AAV vectors. 
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A. Cross administration of different natural AAV serotypes 
Twelve AAV serotypes have been identified to date in humans and over 100 
serotypes in nonhuman primates [24]. All serotypes studied present antigens 
that induce production of neutralizing antibodies (NAB). A potential strategy 
to avoid interference of NAB with primary or secondary AAV-based gene 
delivery is the use of AAV vector serotypes with different antibody reactivity 
profiles but similar affinity for the target tissue. When choosing AAV vector 
serotypes for such “cross-administration” approaches two pivotal aspects 
should be carefully considered.  
Firstly, as would be predicted, homology between AAV serotypes might influ-
ence the possibility of NAB cross-reactivity [22, 25, 26]. Indeed, for closely 
related AAV serotypes 1 and 6 in in vitro studies, cross –neutralization of NAB 
from those serotypes was observed. AAV4, on the other hand, which is a di-
vergent serotype, was only neutralized by the anti-AAV4 NAB from the spec-
trum of anti-AAV1-6 NAB, while AAV5 serotype showed to be inhibited by 
anti-AAV1, 2, 3, 5, and 6 NAB but not by anti-AAV4 NAB [26]. Additionally 
AAV7 and AAV8 have minimal cross-reactivity to other serotypes.  
Secondly, different AAV serotypes have divergent tissue tropisms and differ-
ent transduction efficiencies [27]. As a consequence, depending on the target 
tissue, the choice of alternative AAV serotypes might be limited. 
Cross-administration approaches have proven to be successful in non-human 
primates, when AAV2/5 vector was administered intravenously in animal that 
had pre-existing anti-AAV8 NAB. In contrast, AAV8 vector administration in 
an animal with pre-existing anti-AAV8 NAB did not result in therapeutic pro-
tein expression [28]. Effective cross-administration strategy in vivo without a 
significant cross-inhibitory effect was also observed after cross-administration 
of AAV1, 2 and 5 serotypes in mouse skeletal muscle [29]. 
Although this approach has proven to be successful in the research setting, it 
should be noted that changing serotypes, also changes the drug from regulato-
ry point of view and this would necessitate separate costly drug approval pro-
cedures for every serotype used.  
5 
113 
B. Genetic AAV capsid  
Extensive efforts have been directed towards the development of new artifi-
cial, less immunogenic AAV capsid variants. Conceptually, genetic modifica-
tion of the regions that contain immunogenic AAV capsid epitopes could be 
an approach to escape pre-existing NAB binding and neutralization of modi-
fied AAV capsid. One of such strategies involves targeted modifications of 
identified antigenic regions of AAV capsid [21]. Such rational design was for 
instance investigated by Huttner at al. who demonstrated that insertion of 
different ligands at position 587 in AAV2 VP1 protein allow the transduction 
of cells in the presence of anti-AAV2 NAB [30]. Another group successfully 
employed a directed evolution strategy to generate large AAV2 mutant capsid 
library followed by high-throughput selection process to isolate mutants 
which evade NAB formation [31].  
Even though the AAV capsid engineering methods are promising, none of the 
currently identified AAV capsid mutants are completely resistant to NAB and 
accumulated mutations in AAV capsid may negatively affect efficiency of gene 
delivery. For example, AAV vector production, purification, stability, infectivi-
ty and tissue tropism might be affected. Finally, the immunogenicity of the 
new AAV capsids should be carefully investigated to assess whether they 
would be suitable for re-administration purposes.  
C. Chemical modifications of the AAV capsid  
Chemical polymers are used for steric stabilization of drug carrier systems 
such as lipoplexes, nanoparticles, and liposomes. Chemical polymers are coat-
ing materials that form a protective hydrophilic layer that limits the interaction 
with blood components. Coated nanoparticles are not efficiently absorbed by 
macrophages and therefore show reduced immune responses. The best char-
acterized protein stabilizer material is polyethylene glycol (PEG) and its use 
has been approved in several therapeutic products. PEG is generally non-toxic 
and it extends the half-life of proteins with a reduction of immune responses. 
The attachment of chemical ligands to AAV capsid could potentially protect 
the AAV capsid from binding of NAB. Several groups have tested AAV cap-
sid coating with PEG and other polymers [32-34] but  this has resulted in a 
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moderate protection of AAV capsid against NAB at best, and in some cases 
the modification caused impaired AAV infectivity [34].  
Hence, chemical conjugation of polymers to AAV capsids remains challenging 
and needs to be further developed. The current technology is not satisfactory 
as it does not fully prevent immunogenicity and may cause a loss of AAV in-
fectivity. 
D. Physical removal of circulating anti-AAV NAB  
Plasmapheresis is an extracorporeal blood component separation technique 
which is currently used in the clinic to remove high-molecular-weight sub-
stances such as autoantibodies, immune complexes, cryoglobulins, and bacte-
rial lipopolysaccharides [35]. Plasmapheresis may be used to remove antibod-
ies from the bloodstream, thereby preventing them from binding to their tar-
gets. Due to the fact that plasmapheresis does not interfere with antibody pro-
duction, the therapeutic effect generally is only transient. Plasmapheresis was 
used as a strategy to lower anti-AAV NAB, and different groups have report-
ed promising results. Nonetheless, plasmapheresis by itself seems to be an 
option only for patients that have relatively low anti-AAV NAB titers [36, 37]. 
Physical contact between anti-AAV NAB in blood and injected AAV vector 
can be also prevented by specific delivery technologies. For delivery of AAV 
vectors to the liver in individuals with NAB, specific portal vein injection 
strategies were developed. The first approach involves portal vein branch 
flushing with saline that is directly followed with AAV8 vector injection. The 
second method is based on injection of the vector into the portal vein with 
the use of balloon catheter. Both of the methods proved to be similarly effec-
tive, but second is considered to be safer [38, 39]. This approach needs to be 
further investigated in order to determine the possibility of its application 
when high titers of NAB are present.   
E. Immunosuppression  
Immune suppression (IS) is used in the clinical practice to reduce or prevent 
immune response in organ transplantation and to treat autoimmune diseases. 
IS regimens are based on combinations of drugs such as glucocorticoids, anti-
5 
115 
proliferative and antimetabolite agents, calcineurin inhibitors, rapamycin in-
hibitors, and immune cell depleting or nondepleting monoclonal antibodies. 
Immunosuppressive drugs have many side effects and treatment with them 
increases susceptibility to opportunistic infections or chance of cancer occur-
rence.  
For reduction of anti-AAV NAB titers B cell targeting drugs, as bortezomib 
or anti-CD20 monoclonal antibody have been investigated. Bortezomib, 
which is a proteasome inhibitor that is approved for the treatment of multiple 
myeloma, can eliminate both short- and long-lived plasma cells by activation 
of the terminal unfolded protein response [40]. Unfortunately the bortezomib-
induced reduction in the levels of anti-AAV NAB was not sufficient to allow 
for re-administration of AAV vector. This limitation was related to residual 
anti-AAV NAB levels and bortezomib’s inability to completely deplete 
memory B cells that are re-activated upon AAV vector re-administration 
(Karman 2010). The use of anti-CD20 antibody (rituximab) alone [41] or in 
combination with cyclosporine A [42] also showed only partial efficacy in 
lowering the anti-AAV NAB titer.  
Novel IS approaches can specifically target CD4+ T cells. Targeting of CD4+ 
T cells in mice with non-depleting anti-CD4 antibody and cyclosporine A at 
the time of AAV delivery resulted in inhibition of the primary induction of 
anti-AAV NAB and it allowed for efficient re-administration of the same 
AAV serotype [43]. This IS strategy has to be further investigated for efficacy 
and safety in non-human primates before possible clinical application in AAV-
based gene therapy. It also remains unknown whether this approach will 
prove to be effective in case of already established anti-AAV NAB titers (pre-
existing anti-AAV NAB) which at the moment exclude many patients from 
AAV-based gene therapy. 
F. Adsorption of NAB against AAV capsid 
The principle of antibody adsorption was first demonstrated in gene therapy 
studies with adenovirus studies in which antibodies directed against adenoviral 
capsid were depleted from rabbit serum with the use of chromatography col-
umns containing bound capsid proteins [44]. Such specific antibody depletion 
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proved to facilitate the transduction with adenovirus [45].  A similar principle 
of antibody adsorption was also studied in AAV-based gene delivery in mice 
by Scallan et al. who demonstrated that the presence of empty AAV capsids, 
which acted as decoys, significantly reduced the neutralization of AAV by anti
-AAV NAB [46]. Mingozzi et al. have recently shown in mice and non-human 
primates that injection of therapeutic AAV vector together with empty AAV 
capsids allows liver transduction in the presence of even high titers of anti-
AAV NAB. An additional factor in their experimental setup was the use of a 
mutant empty AAV capsid that cannot enter target cells but can adsorb anti-
AAV NAB [47].   
 
IV Handling cellular and humoral immune responses 
against transgene product 
Next to the immune responses against the AAV capsid protein, cellular and 
humoral immune responses can be induced against the protein encoded by the 
transgene and it can cause a limited efficacy of the treatment [48]. The devel-
opment of specific immune responses directed against the transgene product 
has been shown to be highly dependent on route of administration, AAV vec-
tor serotype, AAV vector dose, tissue specificity of the promoter and clinical 
profile of the patient.  
Even though, promising pre-clinical experimental data have been obtained 
when targeting the liver [49-54], immune responses against the transgene 
product were reported in case of intramuscular AAV-based gene delivery 
which resulted in a limited efficacy of the treatment [55-57]. The cellular and 
humoral immune responses that can occur against the delivered transgene 
product might result in a loss of transgene expression, as reported in pre-
clinical animal studies [58, 57]. Similarly, in the clinical trial for treatment of 
Duchenne’s muscular dystrophy study in which children were injected intra-
muscularly with AAV-minidystrophin, immune responses against minidystro-
phin were observed and expression of the transgene product was lost over 
time [59, 60].  
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To circumvent the appearance of immune responses against transgene prod-
uct several approaches can be considered. 
A. Immune suppression  
Clinical strategies to avoid immune responses directed at expressed proteins 
include the use of IS regimens. This approach proved to be efficient in pre-
clinical studies using intramuscular AAV gene delivery. For instance, treat-
ment with cyclophosphamide at the time of AAV administration and subse-
quently twice a week for next 6 weeks resulted in a sustained partial correction 
of haemophilia B in a null mutation dog model [61]. Another promising out-
come was obtained when using immunosuppression with a combination of 
anti-thymocyte globulin (ATG), cyclosporine (CSP) and mycophenolate mo-
fetil (MMF) which resulted in long-term expression of canine micro-
dystrophin in skeletal muscle after intramuscular AAV-based delivery into 
canine X-linked muscular dystrophy model. 
Although immune suppression may have some efficacy, in order to ensure 
long-term durability of protein expression, immune-modulating therapeutic 
approaches should facilitate tolerance induction towards the transgene prod-
uct. Importantly, some IS regimens interfere with the induction or mainte-
nance of tolerance towards the transgene. For example, it has been reported 
that administration of MMF, sirolimus and daclizumab resulted in a decrease 
of the Treg population which correlated with formation of inhibitory antibod-
ies against human FIX while none of those was observed when the 2-drug IS 
consisting of MMF and sirolimus was used [62]. 
Many different IS regimen combinations for attenuation of transgene-directed 
immunity in AAV-based gene therapy have been tested in pre-clinical animal 
models with quite promising results [42, 43, 63, 64]. However, some IS drugs 
have significant side-effects and lack antigen-specificity [65], and it is desirable 
to be able to exclude those drugs from future IS approaches in gene therapy. 
B. Alternative AAV vector delivery methods 
An approach that has been recently developed and might be an attractive al-
ternative to IS regimens when targeting the muscle with AAV-based gene de-
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livery are regional intravenous (RI) deliveries instead of intramuscular (IM) 
injections. Toromanoff et al. have demonstrated that IM injections of AAV in 
non-human primates are frequently associated with presence of inflammatory 
infiltrates and the destruction of transduced myofibers necessitating the use of 
IS. In contrast, RI AAV delivery resulted in a stable transgene expression 
without immunosuppressive treatment. It seems that the local vector distribu-
tion in the skeletal muscle is a key factor that triggers the immunogenicity af-
ter IM delivery, and this route of administration results in a high number of 
vector genome copies per cell. On the other hand, RI route of AAV delivery 
resulted in homogenous and wide spread vector distribution and lower vector 
genome copies per cell [66]. Arruda et al. have demonstrated similar results in 
canine skeletal muscle for FIX after RI delivery by AAV2 vector [67].  
C. Tissue-specific promoter use 
Avoiding the overexpression of the transgene product in non-target tissues 
and especially in antigen presenting cells (APCs) is a very important method 
to avoid transgene directed immune responses. Tissue-specific promoters 
have been demonstrated to have an important role in reducing the immune 
responses to the transgene products in pre-clinical animal models, especially in 
muscle directed AAV-based gene therapy for muscular dystrophy [68, 69]. 
D. B-cell mediated tolerance induction 
B lymphocytes can act as antigen presenting cells (APCs) and via this pathway 
they may induce of antigen-specific tolerance [70, 71]. Genetically modified B 
cells have proven to be excellent tolerogenic APCs in several animal models. 
Expression of peptide-immunoglobulin fusion proteins by B cells can induce 
tolerance towards the fused peptide and this results in reduced cellular and 
humoral immune responses against that peptide upon immunization in CFA  
[72-74]. Therefore, transgene product specific tolerance induction using autol-
ogous B-cell gene therapy could be a potential strategy to avoid transgene-
directed immune responses in AAV-based gene therapy.     
E. Exploiting the endogenous microRNA machinery for regulation of 
transgene-directed immune responses 
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MicroRNAs are small non-coding RNAs that are endogenously expressed in a 
tissue-specific manner and play an important role in maintaining their func-
tions and differentiation [75, 76]. They are also important in innate and adap-
tive immunity as they control differentiation of various immune cell subsets 
and their functions [77-79]. 
MicroRNAs are capable of post-transcriptional regulation of gene expression 
when they bind to their specific target sequence. Modification of viral vector 
cassettes with microRNA targets is the latest pursuit to regulate gene expres-
sion in gene therapy. A recently explored strategy to avoid immune responses 
against transgene products in gene therapy took advantage of the activity of 
mir-142-3p, which is a miRNA specifically expressed in antigen presenting 
cells (APCs). Incorporation of mir-142-3p target sequences within a transgene 
sequence has been shown to mediate inhibition of transgene expression in 
haematopoietic lineage cells, including APCs in both in vitro and in vivo setup  
[80]. The use of mir-142-3p target sequences prevented immune responses 
towards the transgene product in mice when a lentiviral vector was used for 
gene delivery targeting the liver [81, 82]. Additionally, our group provided evi-
dence that humoral and cellular immune responses against the transgene prod-
uct can be efficiently reduced by use of mir-142-3p target sequences in AAV-
based intramuscular gene delivery [83]. Boisgerault et al. also applied that 
strategy in intramuscular AAV-based gene delivery settings and confirmed our 
findings [84].  
 
V Concluding remarks 
Significant progress has been made in the use of AAV vectors in human gene 
therapy and the first AAV vector product for treatment of lipoprotein lipase 
deficiency received market authorization in Europe  [85, 86]. Immune re-
sponses observed during AAV gene therapy trials in humans do not appear to 
be a safety risk. However, for future indications, host immune responses 
against AAV vector capsid and the transgene product will need to be more 
effectively addressed. There is a need for the development of safe and effi-
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cient strategies that would allow treatment of patients with pre-existing NAB 
against AAV capsids, re-administration of AAV vectors in case transgene ex-
pression is lost due to natural turnover of the transfected cells and that pre-
vent or treat possible immune responses against the transgene product.  
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Introduction 
Adeno-associated virus (AAV) vector based gene therapy has proven to be 
very promising for the treatment of numerous genetic and inflammatory dis-
orders [1, 2]. It has to be considered that re-administration of the therapy 
might be necessary due to the possibility of decrease of AAV-mediated gene 
expression overtime as a result of the natural turnover of transduced cells. 
This point is particularly valid when considering the treatment of life-long 
diseases. 
The major challenge to achieve a successful re-administration is the presence 
of circulating neutralizing antibodies (NAB) directed against AAV capsids 
which are developed after the first administration of AAV vectors. Those neu-
tralizing antibodies that recognize viral capsid proteins do not allow repeated 
gene transfer with AAV of the same serotype [3, 4, 5] Therefore, strategies 
that would permit a repeated gene delivery need to be developed.  
In order to avoid this problem different AAV vector serotype with different 
antibody reactivity profiles and similar affinity to the target tissue could be 
used for the re-administration. Such serotype switching strategy is referred to 
as cross administration. Cross administration of AAV serotypes for the deliv-
ery of therapeutic protein has a great advantage over the alternative approach 
that involves use of immunosuppressive regimens. The immunosuppression 
strategy can lead to serious side effects and might not be applicable in all clini-
cal settings depending on patient treatment history and health condition. It 
has been reported that AAV serotypes 1 and 5 could be used sequentially for 
re-administration in the muscle as no significant inhibitory cross-reaction were 
reported in vivo in muscle and in vitro in hepatic cell lines [3, 6]. In the present 
study we explored in vivo the efficacy of sequential intravenous administration 
of AAV serotype 5 and 1 for AAV re-administration in the liver.  
Material and Methods 
Ethics statement 
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All animal experiments were approved by the local animal welfare committee 
(University of Amsterdam). 
AAV production 
The AAV vectors batches (AAV5-hAAT-SEAP, AAV5-LP1-hFIX, AAV1-
hAAT-eGFP and AAV1-LP1-hFIX) were produced in insect cells according 
to a technology adapted from R. M. Kotin [7]. The AAV vector batches were 
purified with an AVB sepharose column using the ÄKTA explorer system 
(GE Healthcare). Diafiltration and concentration of the AAV elution in PBS-
/-, 5% sucrose buffer was performed with the use of hollow fiber membrane 
(Spectrum labs). The titer of AAV vector genomes copies (gc/ml) in the final 
product was determined by Taqman QPCR amplification.  
Animal Experiments 
Male C57BL/6 mice (8-10 weeks) were obtained from Harlan and maintained 
in specific pathogen-free conditions at the animal facility.  
In the first experiment mice (n=6/group) were injected intravenously (iv) with 
AAV5-hAAT-SEAP or PBS at week 0. The second intravenous administra-
tion with AAV1-LP1-hFIX, AAV1-hAAT-eGFP or PBS was performed at 
week 3 (Figure 1).  
In the second experiment mice (n=6/group) were injected intravenously (iv) 
with AAV5-hAAT-SEAP or PBS at week 0. The second intravenous admin-
istration with AAV1-LP1-hFIX, AAV5-LP1-hFIX or PBS was performed at 
week 3 (Figure 2). The dose of all the AAV batches that were injected was 
1.46 x 1013gc/kg and injection volume was 10 µl/g. 
For both experiments, blood was collected weekly by submandibular vein 
puncture in tubes containing sodium citrate. Plasma was isolated after centrif-
ugation for 20 min at 2500 g at 4°C and stored at -80°C until further analysis. 
All mice were sacrificed at week 7. Liver tissues were collected and snap fro-
zen in liquid nitrogen with or without pre-fixation in picric acid and stored at -
80°C until further analysis. 
 
6 
133 
6 
Cross administration of AAV5 and AAV1 serotypes  
134 
Assessment of transgenes expression  
Human FIX expression was measured in plasma of mice with the use of FIX 
ELISA kit (VisuaLize™ FIX Antigen Kit, Affinity Biologicals™INC). 
SEAP expression was measured in mouse plasma with the use of chemilumi-
nescent “SEAP Reporter Gene Assay” (Roche).  
GFP expression was assessed by post mortem fluorescent microscopy of liver 
tissue sections of mouse livers that were fixed in picric acid upon harvesting. 
Assessment of anti-AAV5 and anti-AAV1 antibody levels 
Levels of anti-AAV5 antibody in mouse plasma was measured by an anti-
AAV5 specific ELISA. Practically, MaxiSorp® flat-bottom 96-well plates 
(ThermoScientific) were coated with AAV5 capsid and anti-AAV5 antibody 
level in samples was detected with 1:1000 rabbit anti-mouse Immunoglobu-
lins/HRP (DAKO).  
Level of anti-AAV1 antibody in mouse plasma was measured by anti-AAV1 
specific ELISA. MaxiSorp® flat-bottom 96-well plates (ThermoScientific) 
were coated with AAV1 capsid and anti-AAV1 antibody level in samples was 
detected with 1:1000 rabbit anti-mouse Immunoglobulins/HRP (DAKO).  
NAB assay against AAV5 and AAV1 capsid 
HEK293T cells were seeded in 96-well plates (Corning) that were pre-coated 
with 0.25% poly L-lysine at a density of 1 x 105cells/well in 100 μl of DMEM 
with 10% FBS and 1% Penicillin/Streptomycin. Cells were incubated over-
night at 37°C in 5% CO2 water jacket incubator. Medium was then removed 
and the following mix was added: AAV5-CMV-GFP for anti-AAV5 NAB 
assay or AAV1-CMV-GFP for anti-AAV5 NAB assay with heat-inactivated 
plasma sample in a total volume of 100 µl of DMEM without phenol red and 
1% Penicillin/Streptomycin. The mix was incubated for 1 hour at 4°C prior to 
addition on the cells. Medium of the HEK293T cells was removed by aspira-
tion, and then the mix was added and incubated for 16-20 h at 37°C. Serial 
dilutions of test plasma that were prepared were: 1:100, 1:200, 1:400, 1:800, 
1:1600, 1:3200, 1:6400, and 1:12800. As a positive control, cells without plas-
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ma addition in the mix were analyzed. After 16-20 h, cells were rinsed with 
PBS, collected after trypsinization and fixed in PBS, 2% Formaldehyde, 1% 
BSA. GFP expression of the cells was analyzed by flow cytometry 
(FACScalibur, Becton Dickinson) in channel FL1 at a wavelength of 530 nm. 
The analysis was performed with the Cellquest Pro software. The percentage 
of inhibition was calculated related to GFP expression measured in AAV 
HEK293T infected cells (no inhibition, 100% expression). Plasma dilutions 
causing a 50% reduction of GFP expression when compared to positive con-
trol, were determined (EC50 determination after sigmoidal curve fit in 
GraphPad Prism software). 
Results 
No cross reactivity of antibodies raised against AAV5 and AAV1 capsids 
was observed. 
Mice were injected intravenously (iv) with AAV5-hAAT-SEAP or PBS at 
week 0. The second intravenous administration with AAV1-LP1-hFIX, AAV5
-LP1-hFIX or PBS was performed at week 3. In order to determine the total 
anti-AAV antibody levels and anti-AAV neutralizing antibody (NAB) levels 
plasma samples of injected animals were analyzed. 
Total anti-AAV5 antibodies were detected in the plasma of all the mice that 
were injected with AAV5 vectors, the levels of antibodies increased over time 
until week 3 and remained stable until the end of the experiment (AAV5-
hAAT-SEAP and AAV5-LP1-hFIX) (Figure 3.A). Similarly, all the mice that 
were injected with AAV1-LP1-hFIX developed antibodies against AAV1 with 
an increase until week 3 after injection was performed (Figure 3.B). As ex-
pected, anti-AAV1 antibodies were not detected in plasma of mice that were 
injected with AAV5-hAAT-SEAP alone, AAV5-LP1-hFIX alone or PBS 
(Figure 3.B) as well as anti-AAV5 antibodies were not detected in plasma of 
mice that were injected with AAV1-LP1-hFIX alone or PBS (Figure 3.A). 
Overall, those results demonstrate the absence of cross reactivity between 
total AAV5 and AAV1 antibodies in our assay. In case of two sequential injec-
tions with AAV5-based vectors, a low level of recognition of AAV1 capsids 
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by anti-AAV5 antibodies was observed, which is probably due to general en-
hancement of immune system responses (Figure 3.B). 
In order to determine the potential of the measured total antibodies to neu-
tralize AAV transduction, neutralizing antibodies assays were performed for 
both AAV5 and AAV1 serotypes. The neutralizing antibody (NAB) titers 
against AAV5 capsid were similar in all the mice injected once with AAV5-
hAAT-SEAP or AAV5-LP1-hFIX. The anti-AAV5 NAB titers were slightly 
higher in the animal group that was injected twice with AAV5 (AAV5-hAAT-
SEAP followed by AAV5-LP1-hFIX) (Figure 4.A). 
Similarly, neutralizing antibody (NAB) titer against AAV1 capsid raised in 
plasma of mice that were injected with AAV1-LP1-hFIX was measured. No 
NAB antibodies against AAV1 capsid were detected in the mice groups that 
were injected with AAV5-hAAT-SEAP alone, AAV5-LP1-hFIX alone or PBS 
(Figure 4.B).  
Our Results demonstrate the absence of cross reactivity between NAB against 
AAV5 and AAV1 capsids.  
Stable dual gene expression after sequential intravenous administration 
of AAV5- and AAV1-mediated gene delivery 
Mice were injected intravenously (iv) with AAV5-hAAT-SEAP or PBS at 
week 0. The second intravenous administration with AAV1-LP1-hFIX, AAV1
-hAAT-eGFP, AAV5-LP1-hFIX or PBS was performed at week 3. In order 
to determine the expression of SEAP and hFIX protein, plasma of injected 
animals was collected weekly, while the eGFP was assessed by post mortem 
fluorescent microscopy of liver tissue sections. 
SEAP expression was detected in the plasma of all the mice injected with  
AAV5-hAAT-SEAP (Figure 5.A, 6.A). This expression increased from week 
0 to week 2 and was stable until sacrifice at week 7. The mice that received 
AAV1-LP1-hFIX in second injection at week 3 showed raising expression of 
hFIX protein in plasma from week 4 which stabilized at week 5 and remained 
stable until sacrifice. At the opposite, the mice which received AAV5-LP1-
hFIX in second injection did not express detectable level of FIX in the plasma 
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(Figure 5.B). It should be noted that the expression level of hFIX protein 
that appeared after injection with AAV1-LP1-hFIX was not influenced by the 
prior injection with AAV5-hAAT-SEAP as the same level of FIX was meas-
ured in the control group that received PBS in first injection and AAV1-LP1-
hFIX in second injection (Figure 5.B.).  
The expression level of hFIX protein in plasma of mice injected with AAV5-
LP1-hFIX was higher than in plasma of mice injected with AAV1-LP1-hFIX. 
This observation confirms previous publications reporting that AAV5 trans-
duces the liver more efficiently than AAV1. However, the level of hFIX pro-
tein measured in the mouse plasma after delivery with AAV1 vector is above 
therapeutic level which indicates that AAV1 serotype could also be efficient 
for gene delivery in the liver. 
Successful cross administration of AAV5 and AAV1 vector was also achieved 
with combination of others expression cassettes: AAV5-hAAT-SEAP and 
AAV1-hAAT-eGFP (week 3) when both SEAP (Figure 6.A) and eGFP 
(Figure 6.B.III) were expressed by the injected animals.     
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Discussion 
The study presented in this chapter demonstrates the feasibility of re-
administration of AAV-based vectors when using sequentially the serotypes 5 
and 1 for liver targeting. We have shown that the anti-AAV neutralizing anti-
bodies (NAB) were not cross reactive between the serotypes 5 and 1 and that 
a high level of gene expression was observed after sequential delivery of re-
porter genes from both AAV5 and AAV1 vectors. In contrast, the re-
administration of the same serotype (AAV5) was unsuccessful due to the total 
inhibition of secondary AAV5 transduction by anti-AAV5 NAB. Our data 
confirms the previously reported in vitro study where the cross-reactivity and 
neutralization mechanisms between AAV1 and AAV5 serotypes were exam-
ined and no cross-reactivity between them was demonstrated [5]. 
The cross administration approach with AAV5 and AAV1 appears to be effi-
cient for hepatic gene transfer as a high level of gene expression was measured 
for both reporter genes used (SEAP and hFIX). It should also be noted that 
despite the fact that hFIX protein expression level after delivery by the AAV1 
serotype is lower than after delivery with AAV5 vector, it remains above the 
defined therapeutic level. All together, these data indicate that AAV1 serotype 
is also a good candidate for liver targeting. However, further evaluation of the 
efficiency of AAV5 and AAV1 cross administration for liver targeting is nec-
essary and non-human primate studies need to be performed in order to eval-
uate the future clinical relevance of such approach. Despite the fact that this 
approach has proven to be successful and could be a good option for many 
patients, changing serotypes, also changes the drug from regulatory point of 
view and that implies separate costly drug approval pathways for every sero-
type used and that certainly is a limiting factor.  
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Abstract 
Adeno-associated virus (AAV) vector-based gene therapy has proven to be 
effective in both clinical and pre-clinical settings. However, a successful re-
administration of the therapy remains a challenge due to development of neu-
tralizing antibodies (NAB) against the AAV capsid after the first administra-
tion. Therefore, exploration of strategies to minimize existing anti-AAV NAB 
to a level that would allow re-administration is of great interest.  
In this study we evaluated the potential of a combined therapy of bortezomib 
and anti-CD20 monoclonal antibody, to reduce the pre-existing humoral im-
munity to AAV in mice. 
The combination of bortezomib and anti-CD20 failed to reduce high anti-
AAV1 NAB titer to a level that would permit re-administration of AAV1. In 
contrast, this immunosuppressive treatment prevented immune response 
against the immunogenic protein (ovalbumin) delivered as a transgene by  
AAV1.  
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Introduction 
Recombinant adeno-associated viral vectors (AAVs) show great promise for 
gene therapy in a variety of different genetic disorders [1- 3]. AAV vectors 
have an excellent safety profile [4, 5] and were shown to mediate a stable ther-
apeutic transgene expression in several non-clinical studies [1, 6-9] and more 
recently in clinical studies [10-13].  The majority of the transgenic proteins are 
expressed from episomal, double stranded DNA [14]. This characteristic rais-
es the possibility that transgene expression will decline overtime with the natu-
ral turnover of transduced cells. Therefore, repeated  administration may be-
come necessary to maintain expression of the transgenic protein at therapeutic 
levels. The major challenge in a successful re-administration of AAV vectors, 
is the presence of neutralizing antibodies (NAB) that develop after the first 
administration. Those neutralizing serotype-specific antibodies directed to-
wards the viral capsid proteins are reducing efficient gene transfer with rAAV 
of the same serotype [15, 16]. Therefore, the generation of a humoral immune 
response is limiting the use of the “vector of choice” more than once which is 
a potential concern for life–long chronic disorders for which re-administration 
might have to be considered. Hence, strategies to decrease existing anti-AAV 
NAB titers need to be explored. 
Bortezomib, a selective inhibitor of the 26S proteasome [17, 18] has been 
shown to significantly decrease AAV specific humoral immune responses af-
ter AAV-based gene delivery in mice [19]. However, this inhibition was only 
partially effective and insufficient to allow subsequent re-administration with  
a recombinant AAV vector of the same serotype [19]. This limitation was 
shown to be due to the combination of residual antibody levels and the  ina-
bility of bortezomib to completely deplete the memory B cells [19]. 
In this study, we explored the potential of a immune suppression protocol for 
which bortezomib was combined with an anti-CD20 monoclonal antibody, 
targeted against pre-B cells, mature B cells and memory B cells [20, 21], to 
reduce level of AAV specific NAB. The efficacy of the combined immuno-
suppressive regimen was challenged by injecting mice with AAV1 carrying an 
expression cassette for ovalbumine (OVA).  
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Materials & methods  
Study Design 
C57BL/6 mice (males, age 6-8 weeks) were obtained from Harlan Laborato-
ries, the Netherlands (n=6 per group). The experimental protocol was ap-
proved by the ethical committee for animal welfare of the AMC (Academic 
Medical Center, Amsterdam, the Netherlands). The general procedure is sum-
marized in Figure 1. Mice received intramuscular injection of AAV1-CMV-
OVA at day 0, at 1 x 1013gc/kg or PBS/5% sucrose. Blood was drawn weekly 
and at sacrifice. Treatment was initiated with three different experimental regi-
ments. A group receiving mono-therapy with bortezomib (velcade) at day 28, 
33 and 36, a group receiving mono-therapy with anti-CD20 antibody 
(eBioscience, clone: AISB12) at day 22 and 27,  a group receiving poly-therapy 
with both bortezomib (day 28, 33 and 36) and anti-CD20 (Day 22 and 27). 
Anti-CD20 was administered intraperitoneal at 100 μg/mouse; bortezomib 
was administered intravenously at 0.75 mg/kg. The control groups were mice 
injected with PBS and mice injected with AAV1-CMV-OVA only.  
AAV vector production and characterization 
AAV vector (AAV1-CMV-OVA) was produced in insect cells according to a 
technology adapted from R. M. Kotin R.M. Kotin [24]. It was purified with an 
AVB sepharose column using the ÄKTA explorer system (GE Healthcare). 
Diafiltration and concentration of the AAV elution in PBS-/-, 5% sucrose 
buffer was performed with the use of hollow fiber membrane (Spectrum labs). 
The titer of AAV vector genomes copies (gc/ml) in the final product was de-
termined by Taqman QPCR amplification.  
Virus neutralizing assay 
HEK293T cells were seeded in 96-well plates (Corning) that were pre-coated 
with 0.25% poly L-lysine at a density of 1 x 105cells/well in 100 μl of DMEM 
with 10% FBS and 1% Penicillin/Streptomycin. Cells were incubated over-
night at 37°C in 5% CO2 water jacket incubator. Medium was then removed 
and the following mix was added: AAV5-CMV-GFP for anti-AAV5 NAB 
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assay or AAV1-CMV-GFP for anti-AAV5 NAB assay with heat-inactivated 
plasma sample in a total volume of 100 µl of DMEM without phenol red and 
1% Penicillin/Streptomycin. The mix was incubated for 1 hour at 4°C prior to 
addition on the cells. Medium of the Hek293T cells was removed by aspira-
tion, and then the mix was added and incubated for 16-20 h at 37°C. Serial 
dilutions of test plasma that were prepared were: 1:100, 1:200, 1:400, 1:800, 
1:1600, 1:3200, 1:6400, and 1:12800. As a positive control, cells without plas-
ma addition in the mix were analyzed. After 16-20 h, cells were rinsed with 
PBS, collected after trypsinization and fixed in PBS, 2% Formaldehyde, 1% 
BSA. GFP expression of the cells was analyzed by flow cytometry 
(FACScalibur, Becton Dickinson) in channel FL1 at a wavelength of 530 nm. 
The analysis was performed with the Cellquest Pro software. The percentage 
of inhibition was calculated related to GFP expression measured in AAV 
HEK293T infected cells (no inhibition, 100% expression). Plasma dilutions 
causing a 50% reduction of GFP expression when compared to positive con-
trol, were determined (EC50 determination after sigmoidal curve fit in 
GraphPad Prism software). Plasma samples were considered to have neutral-
izing activity if the lowest plasma dilution inhibited vector transduction by at 
least 50%, as described before [25, 26, 27, 28].  
Assessment of anti-OVA antibody level  
Level of anti-OVA antibody in mouse plasma was measured by anti-OVA 
specific ELISA. Nunc MaxiSorp® flat-bottom 96-well plates 
(ThermoScientific) were coated with 0.5 µg/ml OVA protein and anti-OVA 
antibody level in samples was detected with 1:1000 rabbit-anti-mouse-HRP 
(DAKO).    
Statistical analysis 
Results are presented as means (+/-standard error of the mean (SEM). Statis-
tical analyses were performed using Prism 5.0 (GraphPad). Data were ana-
lyzed using a 2 way ANOVA, followed by Bonferroni post hoc test for multi-
ple comparisons. 
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Results & Discussion 
Experimental setup 
Mice were injected intramuscularly with 1 x 1013gc/kg of AAV1-CMV-OVA 
or PBS. All the mice were followed for 21 days (3 weeks) for the development 
of NAB against the AAV1 capsid proteins and antibodies against OVA 
transgene product. From day 22, immunosuppressive (IS) therapy was initiat-
ed for 2 weeks, mono-therapy with bortezomib or anti-CD20, and combina-
tion-therapy with bortezomib and anti-CD20 (Figure 1). The drugs were ad-
ministered as follows, three times intravenously at a dose of 0.75 mg/kg for 
the bortezomib (day 28, 33 and 36 of the experiment) and two times intraperi-
toneally at a dose of 100 µg for anti-CD20 (day 22 and 27 of the experiment). 
Humoral response against OVA 
To assess the influence of bortezomib and anti-CD20 on the humoral im-
mune response against the OVA transgene, the levels of specific anti-OVA 
antibodies generated, were assessed over time (Figure 2.A-C). The data ob-
tained show a significant inhibitory effect of bortezomib (67.19 % on day 28 
and 71.18 % on day 35) (Figure 3.A, B) and anti-CD20 ( 61.51% on day 28 
and 44. 38 % on day 35) (Figure 3.A, B) on the humoral response raised 
against the OVA protein when compared to the control without IS. No signif-
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icant additive inhibitory effect on anti-OVA antibody level was observed 
when anti-CD20 and bortezomib treatment were combined (Figure 2.C). The 
inhibitory effect of the IS treatment on the humoral response was transient as 
the antibodies level increased at day 42 of the experiment (Figure 2.A-C). 
Humoral response against AAV1- Neutralizing antibodies (NAB) 
against the AAV1 vector capsid 
To determine the effect of bortezomib and anti-CD20 on the levels of neu-
tralizing antibodies against the AAV1 viral capsid proteins, a neutralizing anti-
body assay was performed on mice plasma samples obtained at days 0, 14, 28, 
42, 56 and 84 (Figure 4). After bortezomib administration (days 28, 33 and 
36), a decrease was observed in the levels of the NAB titers against the AAV1 
capsid at days 42 (13.6%), 56 (26.3%) and 84 (38.7%) when compared to the 
control without IS (Figure 4.A). After anti-CD20 administration (days 22, and 
27), a decrease was observed in the levels of the NAB titers against the AAV1 
capsid (day 84) when compared to the control without IS (35.5%) (Figure 
4.B). The delayed response to the anti-CD20 antibody treatment is consistent 
with the mechanism of action of this antibody [22].  The combination of both 
IS drugs did not show an additive effect on the reduction of anti-AAV1 NAB 
levels (Figure 4.C). The effect of the IS treatment on the humoral response 
was sustained until the end of the observation period as the neutralizing anti-
bodies levels remained low until day 84 for both bortezomib and anti-CD-20. 
However, the anti-AAV NAB titer obtained after treatment (a titer of 2592 ) 
was not low enough to perform re-administration, as previously reported [19].  
We conclude therefore that a combined treatment with bortezomib and anti-
CD20 antibody when a high titer (~3550) of anti-AAV1 NAB has already 
been established cannot reduce the level of those antibodies sufficiently to 
permit re-administration. Therefore, other combination of treatments that 
include additional cellular targets will  be explored in the future. 
Safety 
No weight loss or signs of illness were observed in the mice receiving the im-
munosuppressive drugs alone or in combination. 
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It has been described previously that a dose of 1 mg/kg of bortezomib was 
associated with toxicity in 15% of the animals treated [19] suggesting a narrow 
therapeutic window of this drug. We report that administration of a 0.75 mg/
kg dose of bortezomib either combined with anti-CD20 (100 µg per injection) 
or not did not appear to induce toxicity in mice. 
Additionally thymus, spleen, bone marrow and PBMCs were collected at sacri-
fice, stained for B and T cell markers and analyzed with the use of flow cy-
tometry. We did not observe any significant differences in expression of 
CD19, CD25 or CD138 markers (data not shown) which demonstrate the ab-
sence of long term effects on the adaptive immune system. 
Conclusions and future prospects 
Overall, this study shows that a combination-therapy of bortezomib with an 
anti-CD20 monoclonal antibody was not sufficient to lower a high titer of pre
-existing antibodies against the AAV1 capsid to a level that will allow an effi-
cient AAV1 re-administration. The same drugs alone or in combination were, 
in contrast, efficient in preventing immune response against the immunogenic 
protein (OVA) delivered as a transgene by AAV1. This observation can be 
related to the differences in the kinetic and mechanism of development of the 
humoral immune response against the AAV capsid and the transgene product 
delivered by AAV [23]. 
The two immunosuppressive  molecules used in this study, bortezomib and 
anti-CD20, are mainly targeting pre-B cells, mature B cells and memory B cells 
[20, 21]. Additional cellular inhibitors, as T cell inhibitors, may be required in 
order to bring down the humoral response to the AAV1 capsid. Further stud-
ies are needed in order to evaluate the efficacy of combination treatment that 
targets both B and T cells population as well as the therapeutic benefit in rela-
tion to different NAB levels. 
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Abstract 
Background 
Muscle represents an important tissue target for adeno-associated virus (AAV) 
vector-mediated gene transfer in muscular, metabolic or blood related genetic 
disorders. However, several studies demonstrated the appearance of immune 
responses against the transgene product after intramuscular AAV vector deliv-
ery which resulted in a limited efficacy of the treatment. Use of microRNAs 
(miRNAs) that are specifically expressed in antigen-presenting cells (APCs) is 
a promising approach to avoid those immune responses. Cellular mir-142-3p, 
which is APC-specific, is able to repress translation of its target cellular tran-
scripts by binding to a specific target sequences.  
Methods 
In this study, we explored the potential of mir-142-3p specific target sequenc-
es to reduce or abolish immune responses directed against ovalbumin (OVA), 
a highly immunogenic protein, expressed as transgene and delivered by AAV1 
vector administered intramuscularly. 
Results 
The occurrence of immune responses against OVA transgene following intra-
muscular delivery by AAV have been previously described and resulted in loss 
of OVA protein expression. In the present study we demonstrate that OVA 
protein expression was maintained when mir-142-3pT sequences were incor-
porated into the expression cassette. The sustained expression of OVA pro-
tein over time correlated with a reduced increase in anti-OVA antibody level. 
Furthermore, no cellular infiltrates were observed in the muscle tissue when 
AAV1 vectors containing 4 or 8 repeats of mir-142-3p target sequences after 
OVA sequence were used. 
Conclusions 
The rising humoral and cellular immune responses against OVA protein after 
intramuscular delivery can be efficiently reduced by the use of mir-142-3p tar-
get sequences.  
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Introduction 
Adeno-associated virus (AAV) vectors are one of the most promising systems 
for achieving therapeutic gene delivery for treatment of genetic and chronic 
diseases [1-3]. AAV vectors are able to transduce efficiently a wide variety of 
tissues and can provide long term expression of delivered gene after single 
administration [4-6]. Furthermore, AAV vectors are not associated with any 
pathology and are replication-defective [7]. They have been successfully em-
ployed in treatment of genetic disorders in preclinical studies [8-11] as well as 
in clinical trials [1, 3, 12, 13]. 
Muscle represents an important tissue target for AAV vector-mediated gene 
transfer in muscular [14], metabolic [1] or blood related genetic disorders [1, 
15, 16] such as haemophilia B in which liver directed approach might be not 
possible due to high prevalence of hepatitis in the patient population [17-20]. 
However, several studies demonstrated the appearance of immune responses 
against the transgene product after intramuscular AAV vector delivery which 
resulted in a limited efficacy of the treatment [15, 21, 22]. These observations 
correlate with accumulating evidence that AAV serotypes are able to trans-
duce antigen-presenting cells (APCs) [23-25] and, consequently, can mediate 
the appearance of immune responses against the transgene products in case of 
AAV-based delivery in the muscle [24]. 
The cellular and humoral immune responses that can occur against the deliv-
ered transgene product might result in a loss of transgene expression,  as re-
ported in animal [22, 26] and patient studies [27, 28]. A commonly used ap-
proach to avoid transgene product directed immunogenicity consists of im-
mune suppression protocols. However, immune suppression protocols have 
not always proven to be effective [29], as observed in a clinical study where 
AAV-based gene therapy was used in patients with  Duchenne’s muscular dys-
trophy [27]. Furthermore, immune suppression involves strong, systemic 
drugs that can lead to serious side effects and complications [30, 31]. There-
fore, it is of importance to find an alternative way of tolerance induction to-
wards the transgene product.  
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Cellular microRNAs (miRNAs) are considered to be an important component 
of the gene expression regulatory network [32, 33]. According to miRBase 
(central online repository for miRNA) 21643 mature miRNA are identified in 
168 species. Many miRNAs are expressed in a tissue specific manner and have 
an important role in maintaining tissue specific functions and differentiation 
[34, 35]. Haematopoietic mir-142-3p is a miRNA which is specifically ex-
pressed in antigen presenting cells (APCs) and is able to repress translation of 
its target transcripts by binding to specific target sequences. Fusion of mir-142
-3p target sequences to a transgene sequence has been shown to mediate inhi-
bition of gene expression in haematopoietic lineage cells, including APCs in 
vitro and in vivo [36]. The use of mir-142-3p target sequences was shown to 
prevent immune responses towards the transgene product in mice when a 
lentiviral vector was used for gene delivery targeting the liver [37, 38].  
In the present study we explored the potential of incorporating mir-142-3p-
specific target sequences to reduce or abolish immune responses directed 
against ovalbumin (OVA), a highly immunogenic protein, expressed as 
transgene delivered by an AAV vector administered intramuscularly. 
Materials and methods 
Ethics statement 
All animal experiments were approved by the local animal welfare committee 
(University of Amsterdam). 
Plasmid constructs 
Constructs containing the expression cassette CMV-ovalbumin (CMV-OVA-
WPRE) with 2, 3, 4, 6, 8, 10, 11 and 14 mir-142-3p target sequences (CMV-
OVA-WPRE-mir-142-3pT) were generated by insertion of multiple copies of 
synthesized and annealed oligonucleotides of mir-142-3p target sequences into 
pVD272 plasmid (CMV-OVA-WPRE expressing plasmid) at the 3’-
untranslated region downstream to OVA cDNA and WPRE sequence. The 
presence and orientation of mir-142-3p target sequences was verified by se-
quencing (Figure 1.A). 
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The mir-142-3p expressing plasmid (Figure 1.A) was generated as followed. A 
436 bps fragment of mouse genomic DNA containing the pri-mir-142 
(MI0000167) precursor was cloned by PCR amplification with mmu-mir142f 
( 5 ’ G A A G A A G A G G C T C A T C T G G C 3 ’ )  a n d  m m u - m i r 1 4 2 r 
(5’CAAGTATCAGGG GTCAGGAAG3’) primers into pCR-TOPO Blunt 
plasmid vector (Invitrogen, Carlsbad, CA). Next, the pri-mir-142 expression 
cassette was subcloned into pcDNA6.2-GW/EmGFP-miR vector (Life Tech-
nologies, Grand Island, NY). The presence of pri-mir-142 precursor was veri-
fied by sequencing. Pri-mir-142 expressed two mature miRNAs from 5’ and 3’ 
arm, named mir-142-5p and mir-142-3p. Since we are interested in the mir-
142-3p, we refer to it solely from now on.  
As the negative control, which does not recognize the binding sites for mir-
142-3p, pcDNA6.2-GW/EmGFP-miR-neg (Life Technologies, Grand Island, 
NY) was used and it was named miScr.  
In vitro transfection experiments 
Hek293T cells were co-transfected with the plasmid encoding mir-142-3p and 
with the constructs containing the expression cassette CMV-OVA alone, or 
associated with 2, 3, 4, 6, 8, 10, 11 or 14 mir-142-3p target sequences (CMV-
OVA-mir-142-3pT). Co-transfections were performed with 50 ng of OVA 
expressing plasmids and different amounts of mir-142-3p expressing plasmid 
(5, 10 and 50 ng) with the use of lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s instructions. After 72 hours of incubation, the medium 
was collected and tested for OVA expression in an OVA specific enzyme-
linked immunosorbent assay (ELISA). 
AAV production 
The AAV1 vectors batches (AAV1-CMV-OVA, AAV1-CMV-2xmir-142-3pT, 
AAV1-CMV-4xmir-142-3pT and AAV1-CMV-8xmir-142-3pT) were pro-
duced in insect cells according to a technology adapted from R. M. Kotin [39]. 
The AAV batches were purified with an AVB sepharose column using the 
ÄKTA explorer system (GE Healthcare). Diafiltration and concentration of 
the AAV elution in PBS-/-, 5% sucrose buffer was performed with the use of 
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hollow fiber membrane (Spectrum labs). The titer of AAV vector genomes 
copies (gc/ml) in the final product was determined by Taqman QPCR ampli-
fication. Infectivity of all AAV1 batches was demonstrated in vitro by OVA 
specific ELISA performed on medium from Hek293T that were transduced 
with AAV1 batches with different MOI’s (Multiplicity Of Infection) (data not 
shown). 
Mice experiments 
Male C57BL/6 mice (8-10 weeks) were obtained from Harlan and maintained 
in specific pathogen-free conditions at animal facility.  
In the first in vivo experiment, mice (n=6/group) were injected intramuscularly 
with PBS or 1 x 1014 gc/kg of AAV1-CMV-OVA, AAV1-CMV-OVA-2xmir-
142-3pT, AAV1-CMV-OVA-4xmir-142-3pT or AAV1-CMV-OVA-8xTmir-
142-3pT. In the second in vivo experiment, mice (n=3/group) were injected 
intramuscularly with PBS and two different doses (5 x 1013 gc/kg, 1 x 1014 gc/
kg) of AAV1-CMV-OVA, AAV1-CMV-OVA-2xmir-142-3pT, AAV1-CMV-
OVA-4xmir-142-3pT or AAV1-CMV-OVA-8xmir-142-3pT. Blood was col-
lected weekly by submandibular vein puncture in tubes containing 2 µl of hep-
arin/PBS. Plasma was isolated after centrifugation for 5 min at 5000 rpm and 
frozen at -80°C until further analysis. OVA protein level, anti-OVA antibody 
level and anti-AAV1 antibody level were determined in specific ELISA assays 
as described below.    
Assessment of OVA protein expression, anti-OVA antibody level and 
anti-AAV1 antibody level 
Expression of OVA protein in mouse plasma was measured by OVA specific 
ELISA. Nunc MaxiSorp® flat-bottom 96-well plates (ThermoScientific) were 
coated with 1:2500 rabbit anti-OVA (Fitzgerald) and OVA protein in samples 
was detected with 1:2000 rabbit anti-OVA-biotin (Fitzgerald) and 1:1000 
Streptavidin-HRP (DAKO). Measured OD (450 nm) values between 0 and 
1.5 were determined to correspond to a protein concentration range between 
0 and 450 ng/ml. 
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The level of anti-OVA antibody in mouse plasma was measured by anti-OVA 
specific ELISA. Nunc MaxiSorp® flat bottom 96-well plates 
(ThermoScientific) were coated with 0.5 µg/ml OVA protein and anti-OVA 
antibody level in samples was detected with 1:1000 rabbit anti-mouse Immu-
noglobulins/HRP (DAKO). Measured OD (450 nm) values between 0 and 3 
were determined to correspond to an antibody concentration range between 0 
and 400 ng/ml.    
The level of anti-AAV1 antibody in mouse plasma was measured by anti-
AAV1 specific ELISA. MaxiSorp® flat bottom 96-well plates 
(ThermoScientific) were coated with AAV1 and anti-AAV1 antibody level in 
samples was detected with 1:1000 rabbit anti-mouse Immunoglobulins/HRP 
(DAKO).  
Histological analysis 
Mouse muscle tissue was obtained at sacrifice, 8 weeks after intramuscular 
injections (groups were injected with: PBS, AAV1-CMV-OVA, AAV1-CMV-
OVA-4xmir-142-3pT, and AAV1-CMV-OVA-8xmir-142-3pT) and was fro-
zen in isopentane cooled with liquid nitrogen. Frozen sections, 7µm thick 
were stained for the presence of CD8+ lymphocytes (Rat anti-mouse CD8a, 
clone 53-6.7, BD Pharmigen™), CD4+ lymphocytes (anti-mouse CD4, clone 
LT3T4, BD Pharmigen™ ), neutrophils (Rat anti-mouse mAb NIMP-R14, 
Abcam) and macrophages (Rat anti-mouse, clone F4/80, home-made) and 
OVA protein (anti-OVA antibody; Fitzgerald Inc.). A counter staining with 
haematoxylin was performed.   
Results 
Reduction of OVA expression from CMV-OVA constructs containing 
mir-142-3p targets upon in vitro co-transfection with mir-142-3p ex-
pressing construct  
Constructs containing the expression cassette CMV-OVA alone or linked to 
2, 3, 4, 6, 8, 10, 11 and 14 mir-142-3p target sequences (CMV-OVA-mir-142-
3pT) were generated (Figure 1.A). The inhibitory effect of mir-142-3p on the 
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level of OVA expression in the CMV-OVA constructs containing mir-142-3p 
targets was evaluated in vitro. Increasing the number of mir-142-3p targets re-
sulted in decreased level of OVA protein expression when mir-142-3p expres-
sion plasmid was added in amount of 5 or 10 ng. With the highest amount of 
mir-142-3p (50 ng) the correlation between increasing amount of mir-142-3p 
target sequences and decrease of OVA expression was lost. This result shows 
that mir-142-3p target sequences in the CMV-OVA constructs were recog-
nized by mir-142-3p. However, at a high level of mir-142-3p expression, an 
increasing number of mir-142-3p target sequences did not result in higher in-
hibition of OVA protein expression (Figure 1.B, C). 
Incorporation of mir-142-3p target sequences after OVA transgene se-
quence is correlated with a sustained expression of OVA protein in vivo 
A mouse study was performed to explore the effect of mir-142-3p target se-
quences on OVA expression in vivo. For this study, constructs containing 2, 4 
and 8 mir-142-3p target sequences were chosen. C57BL/6 mice were injected 
intramuscularly with PBS, AAV1-CMV-OVA, AAV1-CMV-OVA-2xmir-142-
3pT, AAV1-CMV-OVA-4xmir-142-3pT or AAV1-CMV-OVA-8xmir-142-
3pT. The expression level of OVA protein was monitored in the plasma of 
injected mice for 4 weeks.  
In control mice that were injected with AAV1-CMV-OVA only, the expres-
sion of OVA protein in the plasma increased until 1 week before returning to 
basal level after 2 weeks. OVA expression remained at base line until sacrifice 
of the mice. In contrast, the plasma of mice injected with AAV1-CMV-OVA 
associated with mir-142-3pT sequences (AAV1-CMV-OVA-mir-142-3pT), 
OVA protein expression was detectable starting from 1 week. In mice that 
were injected with AAV1-CMV-OVA-2xmir-142-3pT, OVA expression was 
stable over the first three weeks following administration before it started to 
rise. In mice that were injected with AAV1-CMV-OVA-4xmir-142-3pT and 
AAV1-CMV-OVA-8xmir-142-3pT, OVA expression was higher compared to 
the level achieved with AAV1-CMV-OVA-2xmir-142-3pT. In addition, OVA 
levels were continuously increasing over the whole observation period of 4 
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weeks. In contrast to the in vitro experiments, OVA protein expression was 
correlated with the increase of mir-142-3pT sequences (Figure 2).  
Based on the higher level of OVA expression observed, AAV1-CMV-OVA-
4xmir-142-3pT and AAV1-CMV-OVA-8xmir-142-3pT were used in the sub-
sequent in vivo study.  
Mir-142-3p target sequences reduce OVA directed immunogenicity fol-
lowing AAV1 intramuscular delivery 
C57/BL6 mice were injected intramuscularly with PBS, AAV1-CMV-OVA 
AAV1-CMV-OVA-4xmir-142-3pT or AAV1-CMV-OVA-8xmir-142-3pT. In 
order to determine a possible influence of the AAV vector dose on the im-
mune response to OVA protein, two different AAV vector doses were used (5 
x 1013 and 1 x 1014 gc/kg) in the present study. The dose-dependent effect of 
mir-142-3p target sequences on the development of humoral immune re-
sponse against the OVA transgene was monitored for 7 weeks, while cellular 
immune responses were assessed by immunohistochemistry at the sacrifice, 8 
weeks after intramuscular injection.  
Elevated levels of anti-OVA antibodies were observed in mice injected with 5 
x 1013 or 1 x 1014 gc/kg of AAV1 (CMV-OVA) (Figure 3.B, D), which corre-
lated with the loss of OVA protein expression (Figure 3.A, C). In some ani-
mals, the anti-OVA antibody level was already reduced after week 4 however 
the OVA protein expression remained absent. In contrast, low anti-OVA anti-
body levels (Figure 4.B, D and 5.B, D) and a sustained expression of OVA 
protein (Figure 4.A, C and 5.A, C) were detected in mice that were injected 
with 5 x 1013 or 1 x 1014 gc/kg of AAV1-CMV-OVA-4xmir-142-3pT or AA-
V1-CMV-OVA-8xmir-142-3pT. To determine whether the decrease of hu-
moral immune response was specific for the OVA protein, anti-AAV1 anti-
body levels were measured in parallel. Anti-AAV1 antibody levels were ob-
served over time in all animals injected with the different AAV1 vectors but 
were absent in PBS injected mice (Figure 6). In all mice injected with AAV1 
vectors anti-AAV1 antibody levels increased until week 3 and remained at this 
level until the end of experiment. The data obtained indicate that the humoral 
immune response was reduced specifically with respect to OVA protein.  
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In addition to the systemic humoral immune response, the local cellular im-
mune response was assessed. Haematoxylin and eosin staining of muscle tis-
sue sections showed the presence of numerous cellular infiltrates in mice in-
jected with 1 x 1014 gc/kg of AAV1-CMV-OVA (Figure 7.B). Specific stain-
ing of these sections showed that the infiltrates were composed of CD8 posi-
tive cells (Figure 8.B), CD4 positive cells (Figure 9.B), macrophages (Figure 
10.B) and neutrophils (Figure 10.F). The cellular infiltrates were shown to 
colocalize with cells expressing OVA (Figure 11.B). No substantial cellular 
infiltrates were observed in the muscle tissue of mice that were injected with 1 
x 1014 gc/kg of AAV1-CMV-OVA-4xmir142-3pT (Figure 7.C, 8.C, 9.C, 
10.C, G) or AAV1-CMV-OVA-8xmir142-3pT (Figure 7.D, 8.D, 9.D, 10.D, 
H), similar to the control mice injected with PBS (Figure 7.A, 8.A, 9.A, 10.A, 
E). 
Inclusion of the mir-142-3pT sequences does not alter mRNA transcrip-
tion of the OVA transgene 
Total RNA from the muscle tissue of mice injected with PBS or 1 x 1014 gc/
kg of AAV1-CMV-OVA, AAV1-CMVOVA-4xmir-142-3pT and AAV1-CMV
-OVA-8xmir-142-3pT was isolated, reverse transcribed into cDNA, and ana-
lyzed by qPCR with primer sets specific for OVA and b-actin. No significant 
differences in the mRNA levels of OVA in the muscle were observed between 
mice injected with AAV1-CMV-OVA, AAV1-CMV-OVA-4xmir-142-3pT or 
AAV1-CMV-OVA-8xmir-142-3pT (data not shown). Additionally, the amount 
of genome copies of (CMV-OVA) DNA present in the muscle of the mice 
was not significantly different between groups (data not shown). Overall, those 
results indicate that the inclusion of mir-142-3pT sequences does not influ-
ence mRNA transcription of the transgene, nor does it influence the infectivi-
ty of the AAV itself. 
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Discussion 
In the present study we report an approach to prolong transgene expression 
after AAV vector-mediated intramuscular delivery by reducing immune re-
sponses directed against the transgene with the use of mir-142-3p target se-
quences.  
AAV has been shown to be a promising vector for therapeutic gene delivery 
to a variety of tissues as a treatment for monogenic diseases [16, 40-43]. Both 
the safety and efficacy of AAV vectors was demonstrated in preclinical and 
clinical studies [1-3, 12, 13]. A very attractive target tissue for AAV vector-
mediated gene therapy is muscle which is easily accessible and rich in vascular 
blood supply, providing an efficient transport system for the secreted pro-
teins. Muscle has been a target tissue for gene therapy for neuromuscular dis-
eases, metabolic disorders [1, 14, 15] and haemophilia, in case the liver cannot 
be considered as a target because of advanced liver diseases [17, 19]. However, 
immune responses against transgene products have been reported after AAV 
vector-mediated intramuscular delivery. They lead to destruction of trans-
duced cells and consequently to loss of transgene expression [28]. Therefore, 
development of strategies to prevent immune responses against the transgene 
product is of great interest. 
Current clinical protocols for avoiding those immune responses involve use of 
drug induced immune suppression. However, they are based on the use of a 
wide range of medications that have various side effects, can lead to many 
complications [16,19] and cannot guarantee the desired effect as demonstrated 
in Duchenne ’s muscular dystrophy clinical trial where immune responses 
against mini dystrophin transgene after intramuscular delivery with AAV vec-
tor were observed despite use of immune suppression [27, 30, 31].  
Many studies report immune responses against the transgene products after 
intramuscularly delivery by AAV vectors. However, when several groups de-
scribe sustained transgene expression without any signs of immune response 
[16, 43], others report cellular and humoral immune responses against neoan-
tigens [26, 28]. The immunogenic potential of the transgene used seems to be 
an important factor in development of immune responses [44-46]. Further-
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more, recent reports show that certain AAV serotypes, specifically AAV1, 2 
and 5 vectors can transduce APCs and mediate potent immune response 
against transgene products [23, 25, 47].  
Therefore, different strategies, such as the use of muscle specific promoters  
[28, 48, 49] are being developed in order to minimize the expression of 
transgene protein in APCs. An attractive alternative to modulate immune re-
sponses against proteins delivered by AAV vectors is miRNA-based regula-
tion of transgene expression. miRNAs are small non-coding RNAs that are 
able to repress translation of target cellular transcripts and have a specific ex-
pression profiles in different tissues [35, 50]. Therefore, the incorporation of 
specific miRNA target sequences after the transgene sequence can repress 
transgene expression in particular cell types. Transgene expression from vec-
tors incorporating target sequences for mir-142-3p, which is the haematopoet-
ic-specific miRNA, was shown to be effectively suppressed in APCs [36-38, 
51, 52]. Therefore, immune responses towards the transgene product could be 
prevented as it has been demonstrated in mice which were injected intrave-
nously with lentiviral vectors [36-38]. Only a few studies have been reported 
in which the mir-142-3pT sequence was part of the expression cassette in 
AAV based vector [53, 54]. In each of those studies the liver was the target 
organ and no efficacy of mir-142-3pT sequences in preventing immune re-
sponses could be demonstrated. Qiao , et al. [54] were unable to draw conclu-
sions from their study as the transgene  expression was lost not as a result of 
immune clearance but due to promoter shut-off. While Contugno , et al. [53] 
did not observe reduction of the immune responses against the transgene nor 
its improved expression in the liver.  
The present study was aimed to explore the potential of mir-142-3p target 
sequences to reduce the immune responses against a transgene product deliv-
ered intramuscularly by AAV. As a model, we used the OVA protein as it has 
been previously described in mice that AAV-mediated intramuscular delivery 
of OVA elicits systemic and local cellular and humoral immune responses 
against OVA [26]. In the time frame of the present study, we were able to 
demonstrate that the systemic OVA expression was maintained when mir-142
-3pT sequences were incorporated to the expression cassette. The sustained 
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expression of OVA over time was associated with a reduced increase in anti-
OVA antibody levels.  
The occurrence of cellular immune responses against OVA transgene follow-
ing intramuscular delivery by AAV have been described previously [26]. In the 
present study, cellular infiltrates were also observed after intramuscular OVA 
delivery by AAV1 vector. However, no cellular immune responses were ob-
served after addition of four or eight repeats of mir-142-3p target sequences 
to the OVA construct, which proves that incorporation of mir142-3p target 
sequences has the potential to reduce local, cellular immune responses as pre-
viously mentioned by Boisgerault, et al. [55]. The decrease of systemic OVA 
protein expression in the plasma of mice that were injected with AAV1-CMV-
OVA correlates with the elevated level of anti-OVA antibodies and the local 
cellular immune responses that colocalize with OVA-expressing cells. Howev-
er, no total clearance of the OVA protein from the muscle tissue was demon-
strated at this time point. This result is different from that reported by Wang 
et al. [26], where local OVA expression in the muscle tissue was still present at 
day 10 but lost at day 30 after AAV delivery. However, it should be noted that 
the AAV serotypes used in those experiments were different as in the present 
study AAV1 (and not AAV2) was used. Furthermore, even though we are 
unable to directly compare the AAV doses used in the two studies, the dose 
used by Wang et al. [26] was reportedly lower. Consequently, the kinetics of 
total clearance of the OVA protein from the muscle tissue may be different. 
In summary, the data obtained in the present study indicate that the rising 
humoral and cellular immune responses against OVA protein after intramus-
cular delivery can be efficiently reduced by use of mir-142-3p target sequences 
that prevent expression of OVA protein in APCs. Overall, this study identifies 
a promising approach for gene therapy applications because it could be ap-
plied as a “safety lock” for any intramuscular AAV vector based therapeutic 
gene delivery. Further investigations are currently pursued to evaluate the im-
pact of mir-142-3pT regulated AAV gene delivery on the normal miRNA pro-
file in the muscle tissue. 
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Lack of tolerance against “self” antigens or “self” commensal bacteria leads to 
autoimmune and inflammatory disorders. Current treatment of those diseases 
is symptomatic, not specific and unfortunately often not effective. Recent ad-
vances in the fields of immunology, cell biology, genetics and bioinformatics 
led to identification of new therapeutic targets and tools for treatment of auto-
immune and inflammatory disorders. One of these novel prevention and 
treatment strategies is induction of immune tolerance. This thesis focuses on 
inducing immune tolerance by regulatory T (Treg) cells generated in vitro by 
activation of naive T cells, or in vivo by adeno-associated virus (AAV)- mediat-
ed delivery of immunomodulatory peptides (Part I). We also explored novel 
methods for tolerance induction with the aim to prevent unwanted immune 
responses directed at AAV vector capsid or immunogenic transgene product 
in the setting of gene therapy (Part II).  
 
Part I  Summary 
Treg cells are a cellular component of the immune system that is specialized in 
suppressing immune responses of effector cells. They can be divided into nat-
urally occurring, thymus-derived Treg (nTreg) cells and induced Treg (iTreg) 
cells which develop outside the thymus under specific conditions. Treg cells 
are responsible for sustaining homeostasis of the immune system, and defi-
ciency of Treg in the system is generally associated with severe inflammatory 
disease states. Treg can be induced ex vivo and have proven to be safe and 
efficient in clinical trials for graft versus host disease [1, 2]. Treg mediated im-
mune tolerance may also be employed as a treatment for diseases with an au-
toimmune or inflammatory background [3-8].  We have studied the latter in 
this thesis and used as in vivo model of inflammatory and autoimmune diseases 
two murine models of Inflammatory Bowel Disease (IBD) (CD45RB transfer 
and trinitrobenzene sulfonate mouse models). These models serve as mouse 
analogs of two chronic inflammatory disorders in humans, Crohn’s disease 
and ulcerative colitis. There is no definite, curative treatment available for 
those conditions and patients require lifelong symptomatic management.  
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Although the exact etiology of the IBD is unknown, it is thought to originate 
as a result of genetic and environmental factors that lead to inappropriate im-
mune responses against dietary or bacterial flora antigens present in the gut 
lumen. Those unwanted immune responses are specifically associated with 
activation of Th17 or Th2 cells and the inability to shut down the resulting 
immune-mediated inflammation. Clearly, inflammatory control by regulatory 
T cell therapy is an attractive treatment strategy for these disease states. A ma-
jor limitation to the use of nTreg cells is availability as they represent only a 
small percentage of the peripheral circulating CD4+T cell population. In order 
to overcome this issue, several groups have developed various methods to 
expand nTreg in vitro while keeping their functionality. Generally, the technol-
ogies are complex, time-consuming and the plasticity of nTreg cells in artificial 
environment during ex vivo expansion may lead to loss of their suppressive 
activity. Additionally their relative mature stage of differentiation makes ex-
pansion in vitro a difficult process.  
In Chapter 2 we describe a new simple method to generate stable and func-
tional human iTreg cells in vitro, providing a simple alternative to previously 
reported techniques. We applied this protocol to murine cells as reported in 
Chapter 3 and demonstrated the functionality of the generated iTreg cells, in 
vivo by their potential to ameliorate the disease phenotype in a CD45RB trans-
fer colitis mouse model. The iTreg cells can also be induced in vivo by a variety 
of immunomodulatory peptides such as for instance cationic host defense 
peptides that have been successfully employed for treatment of inflammatory 
and autoimmune diseases. Among those peptides are recently discovered reg-
ulatory T cell epitopes (Tregitopes) that are derived from immunoglobulin G 
(IgG). Tregitopes, which are stimulators of CD4+CD25+Foxp3+ T regulatory 
cell (Treg) expansion. The anti-inflammatory potential of Tregitope 167 and 
Tregitope 289 has been previously reported [9- 11], but a limiting factor of 
this treatment is the achievement of stable, therapeutic levels of the immuno-
modulatory peptides. A solution to this problem could be a gene therapy ap-
proach that would provide stable peptide expression after the delivery of the 
gene that encodes the peptide of interest and the most promising vector that 
can provide long term expression of the delivered gene after single administra-
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tion is adeno-associated virus (AAV). AAV-mediated gene therapy has been 
effective and safe in preclinical studies as well as in several clinical trials [12-
15]. In Chapter 4, we report the development of an AAV-based approach to 
deliver the anti-inflammatory Tregitope 167 peptide. Tregitope 167 transgene 
was delivered intravenously by an AAV vector in the trinitrobenzene sulfonate 
(TNBS) mouse model of IBD and this resulted in decreased intestinal inflam-
mation. Hence, tolerance induction using Treg might be a future prospect for 
inducing immune tolerance in autoimmune and inflammatory diseases.  
 
Part II Summary 
A main concern with AAV-based gene therapy is the presence of pre-existing 
neutralizing antibodies (NAB) against AAV due to naturally occurring asymp-
tomatic infections with the wild type virus or due to prior treatment with an 
AAV vector. Those anti-AAV NAB can inhibit transduction upon first ad-
ministration in case of pre-existing immunity or upon re-administration with 
the same AAV vector serotype [16-19]. As an alternative to repeated delivery 
of the same AAV serotype, cross-administration, which is the sequential use 
of different AAV serotypes, may be considered. AAV serotypes 5 and 1 have 
been shown to have no significant inhibitory cross-reaction. In Chapter 6 we 
have demonstrated that AAV serotypes 5 and 1 can be used sequentially for re
-administration in the liver with no significant inhibitory cross-reaction ob-
served. A non-human primate experiment is in preparation to confirm the 
data obtained in mice.  
Cross administration of different AAV serotypes for re-administration of ther-
apeutic gene, might not always be feasible, as different AAV serotypes [17] 
have different tissue tropisms. Therefore, a careful selection of appropriate 
AAV serotypes is required when employing this approach for a specific target 
tissue.  
Another option to avoid formation of NAB against AAV vectors would be 
modifying the AAV vector capsid to exclude viral epitopes which induce im-
mune response upon presentation to the immune cells [20]. Finally, the most 
9 
General discussion 
192 
common and widely applied approach to inhibit immune responses is use of 
immunosuppressive drugs [21]. Our group has investigated the influence of 
bortezomib and anti-CD20 alone or in combination therapy on NAB against 
AAV capsid formation (in press). We describe this approach in Chapter 7. 
This approach clearly reduced immune responses, but the effect was short-
lived which indicates that in order to reach satisfying and long-term results 
extended treatment regimens will be necessary. 
Another obstacle that needs to be overcome in AAV-based gene therapy is 
the appearance of immune responses against the expressed protein which 
might result in loss of therapeutic gene expression [22-26]. MicroRNA, mir-
142-3p, which is specifically expressed in antigen presenting cells (APCs) may 
be used as a novel approach to avoid transgene directed immunogenicity. In-
corporation of mir-142-3p target sequences within a transgene sequence has 
been shown to prevent of mRNA and protein expression in haematopoietic 
lineage cells, including APCs in both in vitro and in vivo setup [27]. The use of 
mir-142-3p target sequences prevented immune responses towards the 
transgene product in mice when a lentiviral vector was used for gene delivery 
targeting the liver [28, 29]. Furthermore, our group provided evidence that 
both humoral and cellular immune responses against the transgene product 
can be efficiently reduced by use of mir-142-3p target sequences in AAV-
based intramuscular gene delivery and these experiments are summarized in 
Chapter 8.  
 
Conclusions and future perspectives 
The major achievements reported in this thesis are the identification of two 
novel approaches to generate regulatory T cells with the capacity to ameliorate 
inflammatory response and to restore immune tolerance. Additionally, in rela-
tion to AAV-mediated gene delivery approach to induce tolerance, we devel-
oped new strategies to prevent specific immune responses to the transgene 
product or to the adeno-associated virus (AAV) vector capsid. Initially, we 
provided the basis for further clinical development of cell therapies that in-
volve Treg cells for the treatment of autoimmune and inflammatory diseases 
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by developing approaches to generate both in vitro and in vivo Treg cells. 
Next, we reported a functional approach to reduce the immune responses 
against the transgene product after intramuscular delivery by an AAV vector. 
This strategy could be applied in any AAV vector- based gene therapy target-
ing the muscle where there is a risk of immune responses against transgene 
product. We are currently pursuing further research to evaluate the impact of 
mir-142-3pT regulated AAV gene delivery on the normal miRNA profile in 
the muscle tissue. 
We also investigated the feasibility of cross-administration of AAV vectors, as 
an approach to avoid the problem of formation of neutralizing antibodies 
(NAB) against AAV capsid following primary delivery. Such antibodies may 
interfere with AAV vector transduction upon re-administration of the same 
serotype. We showed that AAV5 and AAV1 could be sequentially delivered 
and the NAB against the capsids of those AAV vectors do not cross-react. 
Hence, this is an attractive approach for therapeutic protein re-administration. 
Our study was performed in a mouse model and should be confirmed in non-
human primates before its possible translation to the human patients. 
We subsequently studied the effect of immune suppressive regimens on neu-
tralizing antibody (NAB) formation against the AAV capsid. Bortezomib and/
or anti-CD20 treatment did not lower the anti-AAV NAB level to a value that 
would permit the re-administration of AAV vector. Therefore, there is a need 
for further studies that would include longer treatment time, dose-finding and 
the introduction of additional immunosuppressive therapeutics that would 
influence not only the B but also the T cell population.  
  
 
 
 
 
 
9 
General discussion 
194 
REFERENCES 
 
1.  Brunstein, CG, Miller, JS, Cao, Q, McKenna, 
DH, Hippen, KL, Curtsinger, J, et al. (2011). 
Infusion of ex vivo expanded T regulatory 
cells in adults transplanted with umbilical 
cord blood: safety profile and detection 
kinetics. Blood; 117: 1061-1070. 
2.  Trzonkowski, P, Bieniaszewska, M, Juscinska, 
J, Dobyszuk, A, Krzystyniak, A, Marek, N, et 
al. (2009). First-in-man clinical results of the 
treatment of patients with graft versus host 
disease with human ex vivo expanded 
CD4+CD25+CD127- T regulatory cells. Clin 
Immunol; 133: 22-26. 
3.  DiPaolo, RJ, Glass, DD, Bijwaard, KE and 
Shevach, EM (2005). CD4+CD25+ T cells 
prevent the development of organ-specific 
autoimmune disease by inhibiting the 
differentiation of autoreactive effector T cells. 
J Immunol; 175: 7135-7142. 
4.  Huter, EN, Stummvoll, GH, DiPaolo, RJ, 
Glass, DD and Shevach, EM (2008). Cutting 
edge: antigen-specific TGF beta-induced 
regulatory T cells suppress Th17-mediated 
autoimmune disease. J Immunol; 181: 8209-
8213. 
5.  Kohm, AP, Carpentier, PA, Anger, HA and 
Miller, SD (2002). Cutting edge: 
CD4+CD25+ regulatory T cells suppress 
antigen-specific autoreactive immune 
responses and central nervous system 
inflammation during active experimental 
autoimmune encephalomyelitis. J Immunol; 
169: 4712-4716. 
6.  Ly, D, Mi, QS, Hussain, S and Delovitch, TL 
(2006). Protection from type 1 diabetes by 
invariant NK T cells requires the activity of 
CD4+CD25+ regulatory T cells. J Immunol; 
177: 3695-3704. 
7.  Manirarora, JN, Kosiewicz, MM, Parnell, SA 
and Alard, P (2008). APC activation restores 
functional CD4(+)CD25(+) regulatory T cells 
in NOD mice that can prevent diabetes 
development. PLoS One; 3: e3739. 
8.  Scalapino, KJ, Tang, Q, Bluestone, JA, 
Bonyhadi, ML and Daikh, DI (2006). 
Suppression of disease in New Zealand 
Black/New Zealand White lupus-prone mice 
by adoptive transfer of ex vivo expanded 
regulatory T cells. J Immunol; 177: 1451-1459. 
9.  Adriaansen, J, Fallaux, FJ, de Cortie, CJ, 
Vervoordeldonk, MJ and Tak, PP (2007). 
Local delivery of beta interferon using an 
adeno-associated virus type 5 effectively 
inhibits adjuvant arthritis in rats. J Gen Virol; 
88: 1717-1721. 
10.   De Groot, AS, Moise, L, McMurry, JA, 
Wambre, E, Van, OL, Moingeon, P, et al. 
(2008). Activation of natural regulatory T 
cells by IgG Fc-derived peptide "Tregitopes". 
Blood; 112: 3303-3311. 
11. Elyaman, W, Khoury, SJ, Scott, DW and De 
Groot, AS (2011). Potential application of 
tregitopes as immunomodulating agents in 
multiple sclerosis. Neurol Res Int; 2011: 
256460. 
12.  Gaudet, D, Methot, J and Kastelein, J (2012). 
Gene therapy for lipoprotein lipase 
deficiency. Curr Opin Lipidol;  
13.  Mueller, C and Flotte, TR (2008). Clinical 
gene therapy using recombinant adeno-
associated virus vectors. Gene Ther; 15: 858-
863. 
14.  Nathwani, AC, Davidoff, A, Hanawa, H, 
Zhou, JF, Vanin, EF and Nienhuis, AW 
9 
195 
(2001). Factors influencing in vivo 
transduction by recombinant adeno-
associated viral vectors expressing the human 
factor IX cDNA. Blood; 97: 1258-1265. 
15.  Nathwani, AC, Tuddenham, EG, Rangarajan, 
S, Rosales, C, McIntosh, J, Linch, DC, et al. 
(2011). Adenovirus-associated virus vector-
mediated gene transfer in hemophilia B. N 
Engl J Med; 365: 2357-2365. 
16.  Calcedo, R, Vandenberghe, LH, Gao, G, Lin, 
J and Wilson, JM (2009). Worldwide 
epidemiology of neutralizing antibodies to 
adeno-associated viruses. J Infect Dis; 199: 381
-390. 
17.  Peden, CS, Burger, C, Muzyczka, N and 
Mandel, RJ (2004). Circulating anti-wild-type 
adeno-associated virus type 2 (AAV2) 
antibodies inhibit recombinant AAV2 
(rAAV2)-mediated, but not rAAV5-mediated, 
gene transfer in the brain. J Virol; 78: 6344-
6359. 
18.  Scallan, CD, Jiang, H, Liu, T, Patarroyo-
White, S, Sommer, JM, Zhou, S, et al. (2006). 
Human immunoglobulin inhibits liver 
transduction by AAV vectors at low AAV2 
neutralizing titers in SCID mice. Blood; 107: 
1810-1817. 
19.  van der Marel, S, Comijn, EM, Verspaget, 
HW, van, DS, van den Brink, GR, Petry, H, 
et al. (2011). Neutralizing antibodies against 
adeno-associated viruses in inflammatory 
bowel disease patients: implications for gene 
therapy. Inflamm Bowel Dis; 17: 2436-2442. 
20.  Maersch, S, Huber, A, Buning, H, Hallek, M 
and Perabo, L (2010). Optimization of stealth 
adeno-associated virus vectors by 
randomization of immunogenic epitopes. 
Virology; 397: 167-175. 
21.  Arruda, VR, Favaro, P and Finn, JD (2009). 
Strategies to modulate immune responses: a 
new frontier for gene therapy. Mol Ther; 17: 
1492-1503. 
22.  Ge, Y, Powell, S, Van, RM and McArthur, JG 
(2001). Factors influencing the development 
of an anti-factor IX (FIX) immune response 
following administration of adeno-associated 
virus-FIX. Blood; 97: 3733-3737. 
23.  Mendell, JR, Campbell, K, Rodino-Klapac, L, 
Sahenk, Z, Shilling, C, Lewis, S, et al. (2010). 
Dystrophin immunity in Duchenne's 
muscular dystrophy. N Engl J Med; 363: 1429-
1437. 
24.  Wang, L, Cao, O, Swalm, B, Dobrzynski, E, 
Mingozzi, F and Herzog, RW (2005). Major 
role of local immune responses in antibody 
formation to factor IX in AAV gene transfer. 
Gene Ther; 12: 1453-1464. 
25.  Wang, L, Dobrzynski, E, Schlachterman, A, 
Cao, O and Herzog, RW (2005). Systemic 
protein delivery by muscle-gene transfer is 
limited by a local immune response. Blood; 
105: 4226-4234. 
26.  Yuasa, K, Sakamoto, M, Miyagoe-Suzuki, Y, 
Tanouchi, A, Yamamoto, H, Li, J, et al. 
(2002). Adeno-associated virus vector-
mediated gene transfer into dystrophin-
deficient skeletal muscles evokes enhanced 
immune response against the transgene 
product. Gene Ther; 9: 1576-1588. 
27.  Brown, BD, Venneri, MA, Zingale, A, Sergi, 
SL and Naldini, L (2006). Endogenous 
microRNA regulation suppresses transgene 
expression in hematopoietic lineages and 
enables stable gene transfer. Nat Med; 12: 585
-591. 
28.  Annoni, A, Brown, BD, Cantore, A, Sergi, 
LS, Naldini, L and Roncarolo, MG (2009). In 
9 
General discussion 
196 
vivo delivery of a microRNA-regulated 
transgene induces antigen-specific regulatory 
T cells and promotes immunologic tolerance. 
Blood; 114: 5152-5161. 
29.  Matsui, H, Hegadorn, C, Ozelo, M, Burnett, 
E, Tuttle, A, Labelle, A, et al. (2011). A 
microRNA-regulated and GP64-pseudotyped 
lentiviral vector mediates stable expression of 
FVIII in a murine model of Hemophilia A. 
Mol Ther; 19: 723-730. 
 
 
 
199 
Addendum 
 
  
& 
Addendum 
& 
201 
Samenvatting 
Inductie van immuun tolerantie in inflammatoire darmziekten en tegen 
adeno-geassocieerde virussen (AAV) 
Dit proefschrift bestaat uit twee delen. Deel I is gericht op de ontwikkeling van 
nieuwe strategieën voor het behandelen van inflammatoire darmziekten (IBD). 
In een experimenteel IBD model, werd een immuun tolerantie bereikt door 
gebruik te maken van in vitro gegenereerde regulatoire T cellen.  Ook werd, met 
behulp van een AAV vector, een methode ontwikkeld om regulatoire T cellen in 
vivo te induceren. Deze inductie van regulatoire T cellen ging gepaard met het 
onderdrukken van ontsteking in een experimenteel IBD model.  
Het is mogelijk dat een immuunreactie ontstaat tegen de AAV capside, of tegen 
het AAV transgen.  Dergelijke reacties zouden succesvolle gentherapeutische 
toepassingen in de weg staan. Het onderzoek beschreven in Deel II van dit 
proefschrift is gericht op tolerantie inductie voor deze factoren om behandeling 
met de AAV vector als onderdeel van een gentherapie strategie, efficiënter te 
maken. 
Deel I 
Inflammatoire darmziekten zijn aandoeningen die gepaard gaan met chronische 
ontstekingen in het maagdarmkanaal en waarvoor geen curatieve behandelingen 
beschikbaar zijn. Behandelstrategieën,  die gebruik maken van cel-, of 
gentherapie, zijn in recent onderzoek succesvol gebleken in het onderdrukken 
van ontsteking en zodoende hoopgevend voor de behandeling van IBD. In dit 
verband is de regulatoire T cel (Treg) een veelbelovende celpopulatie. Treg cellen 
zijn in staat om immuun reacties te doen afnemen en aldus balans in het 
maagdarmkanaal te doen terugkeren. Een probleem is dat de beschikbaarheid 
van natuurlijke Treg (nTreg) cellen erg beperkt is. Ook is het fenotype profiel 
niet stabiel genoeg voor ontwikkelingen ex vivo. Voorts laat de Treg cel zich niet 
makkelijk vermenigvuldigen in vitro.  Daarom biedt het in vitro genereren van 
regulatoire T cel vanuit naïeve T cellen een goed alternatief voor de toekomst om 
deze obstakels te overwinnen. Op het moment zijn diverse strategieën 
beschikbaar om Treg te induceren in vitro. Echter, ieder van deze strategieën kent 
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zijn beperkingen en het is tot op heden nog niet gelukt om in vitro 
geïnduceerde Treg cellen te gebruiken in de kliniek. Het doel van deel I van 
dit proefschrift was zodoende om een nieuwe methode te ontwikkelen om 
Treg cellen in vitro te kunnen produceren. Hoofdstuk 2 beschrijft een activatie 
protocol, waarmee op een eenvoudige wijze, Treg cellen worden gegenereerd 
vanuit naïeve T cellen in vitro. Deze Treg (TregPMA) cellen, remmen de 
proliferatie van geactiveerde leukocyten in een zogenaamde mixed leukocyte 
reaction (MLR), op een dosis afhankelijk wijze. In Hoofdstuk 3 wordt 
aangetoond dat dit protocol ook werkzaam is voor naïeve muis T cellen en dat 
de gegenereerde TregPMA cellen functioneel zijn in vivo, in een experimenteel 
IBD model. In Hoofdstuk 4 wordt gebruik gemaakt van een strategie om 
Treg cellen te induceren in vivo. Met behulp van een AAV vector wordt een 
eiwit in een experimenteel IBD model tot expressie gebracht, te weten een 
Treg epitoop (167). Met behulp van deze AAV vector kon de ontsteking in de 
darm worden verminderd. Bovendien ging dit gepaard met een toename van 
het aantal Treg cellen in de behandelde groep muizen.  
Deel II 
Een belangrijk obstakel voor gentherapie met behulp van op AAV gebaseerde 
virale vectoren, is een humorale immuun reactie tegen de AAV capside. 
Neutraliserende antilichamen (NAB), die ontstaan als reactie op blootstelling 
aan “wild type” AAV of na behandeling met een recombinant AAV vector, 
voorkomen herhaalde blootstelling aan de AAV en maken zodoende een 
volgende gentherapie behandeling minder efficiënt. Hoofdstuk 6 beschrijft 
een methode waarbij het alternerend toedienen van AAV serotype 1 en 
serotype 5, zogenaamde readministratie, wel mogelijk maakt. Daarnaast 
beschrijft Hoofdstuk 7 diverse immuun suppressie strategieën, die de 
humorale immuunreactie tegen de primaire AAV vector doen afnemen. Een 
bijkomende zorg voor gentherapie met behulp van op AAV gebaseerde virale 
vectoren is de mogelijkheid dat een immuunreactie tegen het transgen product 
ontstaat, hetgeen zou kunnen leiden tot verlies van therapeutisch potentieel 
van het gentherapie product. Hoofdstuk 8 beschrijft een methode, die 
gebruik maakt van mir-142-3p expressie om immuunreacties tegen het 
transgeen product te voorkomen. 
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 Streszczenie 
Adresowanie problemów tolerancji immunologicznej w nieswoistym 
zapaleniu jelit oraz transferze genów przy pomocy wirusów 
towarzyszących adenowirusom (AAV) 
Obecna praca doktorska składa się z dwóch części, które dotyczą problemów 
tolerancji immunologicznej w nieswoistym zapaleniu jelit oraz transferze genów 
przy pomocy wirusów towarzyszących adenowirusom. Badania opisane            
w Części I dotyczą rozwoju strategi leczenia nieswoistego zapalenia jelit. 
Osiągneliśmy indukcję tolerancji immunologicznej w mysim modelu 
nieswoistego zapalenia jelit przy użyciu limfocytów T regulatorowych (Treg) 
uzyskanych poprzez specyficzną aktywację limfocytów T naiwnych in vitro. 
Ponadto, wykazaliśmy również, iż limfocyty Treg są indukowane in vivo poprzez 
AAV dostarczające specyficzny gen i przywracają jelitową tolerancję 
immunologiczną. W odniesieniu do stosowania wektorów AAV, w Części II 
niniejszej pracy opisane są badania, które mają na celu zaadresowanie 
problemów dotyczących indukcji tolerancji immunologicznej wobec kapsydów 
wektorów AAV oraz transgenów dostarczonych za pomocą wektorów AAV. 
Zarys Części I 
Rozwój nowych strategii leczenia chorób nieswoistego zapalenia jelit, które są 
uważane za grupę chorób autoimmunologicznych, ma duże znaczenie, gdyż 
obecnie nie ma dla tych chorób skutecznej terapii. Terapia komórkowa oraz 
terapia genowa były ostatnio wykorzystywana do badań, których celem była 
inhibicja stanu zapalnego przewodu pokarmowego. Treg mają zdolność 
tłumienia odpowiedzi immunologicznej oraz utrzymania centralnej równowagi 
immunologicznej. Dzięki temu, limfocyty Treg, mogą zapobiegać  powstawaniu 
stanów zapalnych poprzez indukcję tolerancji immunologicznej. Głównym 
ograniczeniem dla terapeutycznego użytkowania naturalnych limfocytów Treg 
(nTreg) jest ich mała dostępność oraz niestabilny fenotyp podczas ich ekspansji 
ex vivo. Dlatego też zastosowanie indukowanych limfocytów Treg (iTreg) jest 
dobrą alternatywą. Obecnie, istnieje kilka technik służących do wytwarzania 
limfocytów iTreg, jednakże każda z tych technik ma pewne ograniczenia.         
W związku z tym, wprowadzenie nowych, ulepszonych technik do wytwarzania 
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limfocytów iTreg, jest bardzo interesujące. Celem eksperymentów opisanych     
w Rozdziale 2 było stworzenie nowego, prostego sposobu wytwarzania in vitro 
funkcjonalnych i stabilnych limfocytów iTreg z ludzkich CD4+CD25- komórek. 
Wygenerowane limfocyty iTreg (TregPMA) okazały się być funkcjonalne in vitro 
w mieszanej hodowli limfocytów (MLR), gdyż tłumiły proliferację komórek 
biorcy w sposób zależny od dawki. Protokół generacji limfocytów TregPMA in 
vitro został również zastosowany z użyciem komórek mysich. Jest to opisane w 
Rozdziale 3. Funkcjonalność wygenerowanych limfocytów iTreg została 
zobrazowana poprzez złagodzenie zapalenia jelita w mysim modelu 
nieswoistego zapalenia jelita.  
Pośród niedawno podejmowanych badań naukowych, które mają na celu 
wygenerowanie limfocytów iTreg są badania, które użytkują terapię genową i 
komórkową. W Rozdziale 4, zbadana została metoda indukcji limfocytów Treg 
in vivo poprzez wprowadzenie do komórek pewnego genu. Dostarczenie 
regulatorowego epitopu 167 limfocytów T (Tregitope 167) za pomocą wektora 
AAV, wykazało indukcję limfocytów Treg in vivo i złagodzenie 
eksperymentalnego zapalenia jelita. To badanie wykazało, że dostarczenie 
przeciwzapalnego Tregitope za pomocą wektora AAV powoduje indukcje 
tolerancji immunologicznej przez limfocyty Treg, co w konsekwencji może być 
użyte do leczenia chorób o podłożu autoimmunologicznym i zapalnym.  
Zarys Części II 
Główną przeszkodą w dostarczaniu genów za pomocą wektora AAV jest 
humoralna odpowiedź immunologiczna skierowana przeciw białkom kapsydu 
AAV, która pojawia się po pierwszej infekcji wektorem AAV. Przeciwciała 
neutralizujące skierowane przeciw kapsydom AAV blokują ponowną 
transdukcję tym samym serotypem AAV. W Rozdziale 6  zademonstrowaliśmy 
na mysim modelu, iż można skutecznie dostarczyć gen z użyciem wektora AAV 
serotypu 5 a następnie ponownie dostarczyć inny gen z użyciem wektora AAV 
serotypu 1, gdyż przeciwciała neutralizujące skierowane przeciw białkom 
kasydów wektora AAV serotypu 5 nie hamują transdukcji za pomocą wektora 
AAV serotypu 1. W Rozdziale 7 zbadaliśmy zdolność różnych kombinacji 
środków immunosupresyjnych do obniżenia poziomu krążących we krwi 
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przeciwciał neutralizujących przeciwko kapsydom wektorów AAV, które 
pojawiają się po pierwszym podaniu wektora AAV. Celem tego badania było 
określenie strategii leczenia immunosupresyjnego oraz ram czasowych,             
w których obniżenie poziomu przeciwciał neutralizujących przeciwko 
kapsydowi wektora AAV umożliwi ponowne podanie wektora AAV.     
Innym problemem w terapii genowej przy zastosowaniu wektorów AAV jest 
możliwość odpowiedzi immunologicznej skierowanej  przeciw produktom 
transgenów. Ta reakcja immunologiczna może doprowadzić do utraty ekspresji 
terapeutycznego transgenu. Dlatego też, istnieje zapotrzebowanie na określenie 
metod, które doprowadzą do indukcji tolerancji immunologicznej wobec białka 
transgenu. W Rozdziale 8, opisaliśmy możliwość zastosowania sekwencji 
targetowych mir-142-3p w celu uniknięcia reakcji immunologicznej przeciw 
produktowi transgenu, po domięśniowych dostarczeniu wektora AAV.   
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GMP    Good Manufacturing Practices 
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